A Phase 2 interventional study of eltrombopag and Placebo in Purpura, Thrombocytopaenic, Idiopathic, sponsored by GlaxoSmithKline. Completed at 33 sites in 6 countries. Open to participants aged 1 Year to 17 Years. Per ClinicalTrials.gov, last updated 2018-10-12.
Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies testing eltrombopag in Purpura, Thrombocytopenic, Idiopathic — 7 open to participants now, 7 under way, none of them phase 3. eltrombopag · Purpura, Thrombocytopenic, Idiopathic.
Among the 36 studies testing eltrombopag in Purpura, Thrombocytopenic, Idiopathic, this one is the 11th largest by enrollment, is one of 3 that started in 2009, is one of 15 in phase 2, and was the 10th registered.
504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.
Browse Purpura, Thrombocytopenic, Idiopathic studies →7 of the 36 studies testing eltrombopag in Purpura, Thrombocytopenic, Idiopathic are open now, in 3 countries. Recruiting first, the newest first:
Sohag University · Sites in Egypt
Ages 18–75
Renata PLC · Sites in Bangladesh
Ages 18–70
Nahda University · Sites in Egypt
Ages 18–65
Novartis Pharmaceuticals
Ages 5–17
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 18–80
By country, each count listing its studies:
eltrombopag: first FDA approval 2008 (PROMACTA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 103 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (48%) set no upper age limit and 42 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.
This study: 1 Year to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 16 · Phase 3 9 · Phase 4 5
First in 2005; this study’s year is marked. 3 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 82 is above the median of 58 across 377 interventional studies indexed under Purpura, Thrombocytopenic, Idiopathic.
Median enrollment 40 across the 36 interventional studies. Of the 25 that completed or were terminated, 14 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 36 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
11 studies in Purpura, Thrombocytopenic, Idiopathic by GlaxoSmithKline: none open now, none under way, none of them phase 3. Of 11 finished, 6 (55%) have results posted.
Among the 11 studies in Purpura, Thrombocytopenic, Idiopathic by GlaxoSmithKline, this one is the 4th largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2009, is one of 4 in phase 2, and was the 8th registered.
GlaxoSmithKline’s Purpura, Thrombocytopenic, Idiopathic studies by the year they started, since 2005.
1 of the studies testing eltrombopag in Purpura, Thrombocytopenic, Idiopathic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07189910Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologySequential rhTPO and Eltrombopag Following Glucocorticoids for Severe Adult ITP | 2027-11-01 |
Add it to your calendar (.ics) → With an account.
Among the 36 studies testing eltrombopag in Purpura, Thrombocytopenic, Idiopathic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 11 in Purpura, Thrombocytopenic, Idiopathic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Phase II, multi-center, 3 part, staggered cohort, open-label and double blind, randomized, placebo controlled study involving 3 age-determined cohorts (Cohort 1: between 12 and 17 years old; Cohort 2: between 6 and 11 years old; Cohort 3: between 1 and 5 years old). Daily dosing with eltrombopag will begin with 5 patients in the oldest age cohort in an open label fashion, and a review of safety, pharmacokinetic and platelet count data will be performed regularly. If no safety concerns are identified after 12 weeks, 18 additional patients will be randomised to placebo or eltrombopag (2:1 randomisation). After 7 weeks of randomized treatment, all patients will receive eltrombopag in an open label fashion. The total duration of treatment with eltrombopag will be 24 weeks. If at the time of the aforementioned 12 week review of the first 5 patients no safety issues are identified, dosing will begin in the next lower age cohort with an initial group of 5 patients. The same procedure will be followed in terms of safety review and subsequent enrolment and randomisation of the additional patients. Initiation of the younger age cohort will take place once data from the previous has been evaluated. Doses will be adjusted according to platelet counts and tolerability. The study will include a review of the safety data by a Data Safety Monitoring Board.
504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.
This study's enrollment of 82 is above the median of 58 across 377 interventional studies indexed under Purpura, Thrombocytopenic, Idiopathic.
Browse Purpura, Thrombocytopenic, Idiopathic studies →GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
Compared within Purpura, Thrombocytopenic, Idiopathic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Purpura. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
eltrombopag
Drug: eltrombopag
placebo
Drug: Placebo
thrombopoietin receptor agonist
placebo for comparison
Percentage of Participants Achieving a Platelet Count >=50 Giga Cells Per Liter (Gi/L) at Least Once, Between Day 8 and Day 43 (Weeks 1 to 6) of the Randomized Period of the Study (Part 2)
Participants who achieved a platelet count \>=50 Gi/L at least once between Day 8 and Day 43 (first 6 weeks of Part 2) in the absense of rescue treatment were reported. A 95% confidence interval was calculated by the exact binomial method.
Time frame: From Day 8 up to Day 43 of Part 2
Percentage of Participants Achieving Platelet Counts >=50Gi/L During Treatment With Eltrombopag in >= 60% of Assessments Between Day 15 and Day 43 (Weeks 2 Through 6) of the Randomized Treatment Period (Part 2)
Sustained platelet response between the treatment groups was assessed by determining the number of participants who achieved a platelet count \>=50 Gi/L during treatment with eltrombopag in \>= 60% of assessments between Day 15 and Day 43 in the absence of rescue treatment were reported here.
Time frame: Between Day 15 and Day 43 of Part 2
Weighted Mean Platelet Count
The weighted mean platelet count is defined as the area under the platelet-time curve divided by the duration of the treatment (12 weeks). Based on the Analysis of Covariance (ANCOVA) model, the weighted mean platelet count is the sum of the Baseline count plus the age cohort plus the treatment. Baseline was defined as the platelet count taken on Day 1 or within 48 hours prior to the first dose of treatment.
Time frame: Baseline and Day 43 of Part 2
Percentage of Participants Achieving Platelet Counts >=50Gi/L at Any Time During the 24 Weeks of Eltrombopag Dosing During Part 1.
The percentage of participants achieving platelet counts \>=50Gi/L at least once at any time during the 24 weeks of eltrombopag treatment were reported.
Time frame: From Day 1 of treatment up to Week 24 of Part 1
Percentage of Participants Achieving Platelet Counts >=50 Gi/L at Any Time During the 31 Weeks of Eltrombopag Treatment During Part 2/ 3.
The percentage of participants achieving platelet counts \>=50Gi/L at least once at any time during the 24 weeks of eltrombopag treatment during Part 2/3 of the study were reported. Participants randmoized to receive eltrombopag for 7 weeks in Part 2 continued receiving eltrombopag for an additional 17 weeks in Part 2/3 (for a total of 24 weeks of treatment) up to Study Week 24. Participants randomized to receive placebo for 7 weeks in Part 2, received 24 weeks of eltrombopag in Part 2/3 (for a total of 24 weeks of treatment) up to Study Week 31.
Time frame: Part 2/3 up to Study Week 31
Population Pharmacokinetic (PK) Assessment for Eltrombopag for AUC(0-t) During Part 1, 2, and 2/3.
The area under the concentration-time curve over the dosing interval (AUC0-t) data was collected to estimate primary model-based PK parameters. PK samples were collected within 3 hours prior to dosing and 2, 4, 6, 8 and 24 hours after dosing. Doses were normalized to 50mg for comparison. PK samples were collected at each on-treatment visit during Part 1, Part 2, and Part 2/3. The concentration data were pooled across visits to identify population PK and variability parameter estimates and covariate effects. AUC(0-t) is defined as the area under the concentration-time curve over the dosing interval. From the final model, a single value of AUC(0-t) was estimated for each subject, and geometric mean (95% CI) values are presented for each cohort for a 50mg dose.
Time frame: From Day 1 of treatment up to Study Week 31
Population Pharmacokinetic (PK) Assessments for Eltrombopag for Cmax and Ct During Part 1, 2, and 2/3.
The maximum observed concentration (Cmax) and the concentration at the end of the dosing interval (Ct) data were collected to estimate primary model-based PK parameters. PK samples were collected within 3 hours prior to dosing and 2, 4, 6, 8 and 24 hours after dosing. Doses were normalized to 50mg for comparison. PK samples were collected at each on-treatment visit during Part 1, Part 2, and Part 2/3. The concentration data were pooled across visits to identify population PK and variability parameter estimates and covariate effects. From the final model, a single value of Cmax and Ct were estimated for each subject, and geometric mean (95% CI) values are presented for each cohort for a 50mg dose.
Time frame: From Day 1 of treatment up to Study Week 31
Population Pharmacokinetic (PK) Assessments for Eltrombopag for Tmax During Part 1, 2, and 2/3
The time to maximum concentration (tmax) was collected to estimate primary model-based PK parameters. PK samples were collected within 3 hours prior to dosing and 2, 4, 6, 8 and 24 hours after dosing. PK samples were collected at each on-treatment visit during Part 1, Part 2, and Part 2/3. The concentration data were pooled across visits to identify population PK and variability parameter estimates and covariate effects. From the final model, a single value of tmax was estimated for each subject, and geometric mean (95% CI) values are presented for each cohort for a 50mg dose.
Time frame: From Day 1 of treatment up to Study Week 31
Population Pharmacokinetic (PK) Assessments for Eltrombopag for CL/F During Part 1, 2, and 2/3
The apparent plasma clearance following oral dosing of eltrombopag (CL/F) was collected to estimate primary model-based PK parameters. PK samples were collected within 3 hours prior to dosing and 2, 4, 6, 8 and 24 hours after dosing. PK samples were collected at each on-treatment visit during Part 1, Part 2, and Part 2/3. The concentration data were pooled across visits to identify population PK and variability parameter estimates and covariate effects. From the final model, a single value of CL/F was estimated for each subject, and geometric mean (95% CI) values are presented for each cohort for a 50mg dose.
Time frame: From Day 1 of treatment up to Study Week 31
Maximum Duration for Which a Participant Continuously Maintained a Platelet Count of >=50 Gi/L During the 7 Weeks of Eltrombopag Treatment in Part 2
The maximum duration for which a participant continuously maintained a platelet count \>=50 Gi/L in the absence of rescue treatment was calculated and summarized during the 24 weeks of eltrombopag treatment in Part 2. Participants with non-weekly assessments were assumed to have maintained a positive response for each week between two assessments that had positive responses. If a particpant achieved a positive response at an assessment and then achieved a negative response at the next assessment, then it was assumed that the participant had achieved a positive response for one day. Excludes periods from initiation of rescue medication until platelet count falls to below 50Gi/L, irrespective of platelet count
Time frame: From Baseline through Week 7 of Part 2
Maximum Duration for Which a Participant Continuously Maintained a Platelet Count of >=50 Gi/L During the 24 Weeks of Eltrombopag Treatment in Part 2/ 3
The maximum duration for which a participant continuously maintained a platelet count \>=50 Gi/L in the absence of rescue treatment was calculated and summarized during the 24 weeks of eltrombopag treatment in Part 2/3. Participants with non-weekly assessments were assumed to have maintained a positive response for each week between two assessments that had positive responses. If a particpant achieved a positive response at an assessment and then achieved a negative response at the next assessment, then it was assumed that the participant had achieved a positive response for one day. Participants randmoized to receive eltrombopag for 7 weeks in Part 2 continued receiving eltrombopag for an additional 17 weeks in Part 2/3 (for a total of 24 weeks of treatment) up to Study Week 24. Participants randomized to receive placebo for 7 weeks in Part 2, received 24 weeks of eltrombopag in Part 2/3 (for a total of 24 weeks of treatment) up to Study Week 31.
Time frame: From Baseline up to Study Week 31
Percentage of Participants Who Reduced or Discontinued Baseline Concomitant Idiopathic Thrombocytopenic Purpura (ITP) Medications During the 24 Weeks of Eltrombopag Treatment During Part 1.
The participants who discontinued (dis) or had a sustained reduction (red) of a Baseline (BL) ITP medication for at least one day during the period of Day 1 of Part 1 to the last dose of study medication +1 day are reported. The denominator is the number of subjects taking an ITP medication at baseline. For participants in Part 1, Baseline is defined as Day 1 of Part 1. A sustained reduction is defined as reduction for 4 weeks or more. An attempted red or dis is a decrease in the dose or frequency from the BL dose or frequency of an ITP medication for at least one day during the period Part 1 Day 1 to the last dose of study medication + 1 day.
Time frame: From Baseline up to Week 24+ 1 day of Part 1
Percentage of Participants Who Reduced or Discontinued Baseline Concomitant ITP Medications During the 24 Weeks of Eltrombopag Treatment During Part 2/ 3
Participants who discontinued (dis) or had a sustained reduction (red) of a Baseline (BL) ITP medication for at least one day during the period of Day 1 of Part 2/3 to the last dose of study medication +1 day are reported. The denominator is the number of subjects taking an ITP medication at baseline. For participants randomized to placebo in Part 2, BL is defined as Week 7 of Part 2. For participants randomized to eltrombopag in Part 2, BL is defined as Day 1 of Part 2. A sustained reduction is defined as reduction for 4 weeks or more. An attempted reduction or discontinuation is a decrease in the dose or frequency from the BL dose or frequency of an ITP medication for at least one day during the period Part 2/3 Day 1 to the last dose of study medication + 1 day.
Time frame: From Baseline to the end of treatment up to Week 31 + 1 day of Part 2/3
Number of Participants Who Required a Protocol-defined Rescue Treatment During Part 2/3
Rescue treatment was defined as either a new immune (idiopathic) thrombocytopenic purpura (ITP) medication, an increase in the dose of a concomitant ITP medication from Baseline, a platelet transfusion, or a splenectomy. For particpants randomized to placebo in Part 2, Baseline is defined as Week 7 of Part 2. For participants randomized to eltrombopag in Part 2, Baseline is defined as Day 1 of Part 2. Participants randmoized to receive eltrombopag for 7 weeks in Part 2 continued receiving eltrombopag for an additional 17 weeks in Part 2/3 (for a total of 24 weeks of treatment) up to Study Week 24. Participants randomized to receive placebo for 7 weeks in Part 2, received 24 weeks of eltrombopag in Part 2/3 (for a total of 24 weeks of treatment) up to Study Week 31.
Time frame: From Baseline to the end of treatment up to Week 31 + 1 day of Part2/3
Kids' ITP Tool (KIT) Questionnaire Total Score at Baseline, Week 6, Week 12, and Week 24 as Assessed Using the KIT Questionnaire During the Dose Finding Period, Part 1
The KIT questionnaire measures the impact on the quality of life determined by the participant and the guardian by self reported outcomes at Baseline or the Screening Visit, after 6 weeks of treatment, after 12 weeks of treatment and at the end of treatment or withdrawal from the study. The KIT total score is calculated from the scores of each of the individual questions from Q1 - Q26 (excluding any answer that is 'Not applicable'). The code list used for the individual question scores is: 1 = never, 2 = seldom, 3 = sometimes, 4 = often, 5 = always and 9 = not applicable. The range of values the total score can take is 0 (worst) to 100 (best). For subjects under the age of six, the family questionnaire (parental proxy) has been used.
Time frame: Baseline, Week 6, Week 12, and Week 24 of Part 1
Kids' ITP Tool (KIT) Questionnaire Total Score at Baseline and Week 6as Assessed Using the KIT Questionnaire During the Randomized Period, Part 2
The KIT questionnaire measures the impact on the quality of life determined by the participant and the guardian by self reported outcomes at Baseline or the Screening Visit, after 6 weeks of treatment or withdrawal from the study. The KIT total score is calculated from the scores of each of the individual questions from Q1 - Q26 (excluding any answer that is 'Not applicable'). The code list used for the individual question scores is: 1 = never, 2 = seldom, 3 = sometimes, 4 = often, 5 = always and 9 = not applicable. The range of values the total score can take is 0 (worst) to 100 (best). For subjects under the age of six, the family questionnaire (parental proxy) has been used.
Time frame: Baseline and Week 6 of Part 2
Kids' ITP Tools (KIT) Questionnaire Total Score at Baseline, Week, 6, Week 12, and End of Treatment Visit as Assessed Using the KIT Questionnaire During the Eltrombopag Open-Label Period, Part 2/3
The KIT questionnaire measures the impact on the quality of life determined by the participant and the guardian by self reported outcomes at Baseline or the Screening Visit, after 6 weeks of treatment, after 12 weeks of treatment and at the end of treatment or withdrawal from the study. The KIT total score is calculated from the scores of each of the individual questions from Q1 - Q26 (excluding any answer that is 'Not applicable'). The code list used for the individual question scores is: 1=never, 2=seldom, 3=sometimes, 4=often, 5=always and 9=not applicable. The range of values the total score can take is 0 (worst) to 100 (best). For subjects under the age of six, the family questionnaire (parental proxy) has been used.
Time frame: From Baseline to end of treatment up to Study Week 31
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2
The WHO Bleeding Scale is a measure of bleeding severity with the following grades: Grade 0 = no bleeding, Grade 1 = petechiae, Grade 2 = mild blood loss, Grade 3 = gross bleeding and Grade 4 = debilitating blood loss. The WHO grades were dichotomized into the following categories: no bleeding=Grade 0; any bleeding=Grades 1 to 4; no clinically significant bleeding=Grades 0 to 1; clinically significant bleeding=Grades 2 to 4. For participants randomized to Placebo in Part 2, Baseline defined as Week 7 of Part 2. For participants randomized to Eltrombopag in Part 2, Baseline defined as Day 1 of Part 2.
Time frame: From Baseline through Week 7 of Part 2
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2/3
The WHO Bleeding Scale is a measure of bleeding severity with the following grades: Grade 0 = no bleeding, Grade 1 = petechiae, Grade 2 = mild blood loss, Grade 3 = gross bleeding and Grade 4 = debilitating blood loss. The WHO grades were dichotomized into the following categories: no bleeding=Grade 0; any bleeding=Grades 1 to 4; no clinically significant bleeding=Grades 0 to 1; clinically significant bleeding=Grades 2 to 4. For participants randomized to Placebo in Part 2, Baseline defined as Week 7 of Part 2. For participants randomized to Eltrombopag in Part 2, Baseline defined as Day 1 of Part 2.
Time frame: From Baseline of Part 2/3 through Follow-up
Number of Participants With the Indicated Clinical Chemistry Parameter Falling Outside of the Reference Range Any Time Post-Baseline During Part 1, Part 2, and Part 2/3
Clinical chemistry parameters included: aspartate amino transferase (AST, reference range \[RR\]: 0-38 International Units per Liter \[IU/L\]), alkaline phosphatase (ALP: RR: 50 - 375 IU/L), total bilirubin (RR: 3.42 - 22.23 micromoles \[umol\]/L), albumin grams \[g/L\], alanine amino transferase (ALT, RR: 5-30 IU/L), prothrombin international normalized ratio (PT INR, RR-0.9 - 1.2), activated partial thromboplastin time (APTT, RR: 24.2 - 32.9 seconds), glucose (RR: 4.107- 6.55018 millimoles \[mmol\]/L), potassium (3 - 5 mmol/L), and sodium (135 - 143 mmol/L). Baseline values were obtained at Day 1. The number of participants with the indicated clinical chemistry data outside of the reference range (with high and low) any time post-Baseline are presented. Anytime post-Baseline assesments included any scheduled and unscheduled post-Baseline assessment
Time frame: Post-Baseline from Week 1 through Follow-up up to Study Week 35
Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline During Part 1, Part 2, and Part 2/3
Hematology parameters included: erythrocytes (RR: 4.2 - 6.1 teragrams per liter \[TI/L\]), hemoglobin (RR: 125 - 165 g/L), hematocrit (RR: 0.36 - 0.46), platelets (RR: 170 - 430 gigagrams per liter \[GI/L\]), mean platelet volume (MPV, RR: 4 - 14 femotoliter \[fL\]), leukocytes (RR: 3.4 - 11.2 GI/L), total neutrophils (RR: 2.1 - 4.9 GI/L), lymphocytes (RR: 1.4 - 2.9 GI/L), monocytes (RR: 0.2 - 0.9 GI/L), eosinophils (RR: 0.2 - 0.7 GI/L), and basophils (RR: 0.02 - 0.12 GI/L). Baseline values were obtained at Day 1. The number of participants with the indicated hematology parameters data outside of the reference range (with high and low) any time post-baseline are presented. Anytime post-Baseline assesments included any scheduled and unscheduled post-Baseline assessment
Time frame: Post-Baseline from Week 1 through Follow-up up to Study Week 35
Number of Participants With the Indicated Renal Parameters Falling Outside of the Reference Range Any Time Post-Baseline During Part 1, Part 2, and Part 2/3
Renal parameters included: creatinine (RR: 44.2 - 88.4 umol/L), creatinine clearance derived (RR: 89.0 - 165.0 milliliter per minute \[ ml/min\]), protein/creatinine (RR: 0.113- 18.0992 microgram per millimoles \[mg/mmol\]), and urea (RR: 1.785- 8.925 mmol/L). Baseline values were obtained at Day 1. The number of participants with the indicated renal parameters data outside the reference range (with high and low) any time post-Baseline are presented. Anytime post-Baseline assesments included any scheduled and unscheduled post-baseline assessment
Time frame: Post-Baseline from Week 1 through Follow-up up to Study Week 35
Number of Participants With a Positive Urine Microscopy Parameters Any Time Post-Baseline During Part 1
Urine microscopy included Red Blood Cell (RBC) casts, white blood cell (WBC) casts, and epithelial renal tubular cell casts. Urine microscopy data was reviewed by the Medical Monitor in order to classify the results as positive or negative. The number of participants with a positive result at any time post Baseline were reported. A positive result indicated if the result was positive for at least one of RBC casts, WBC casts, or epithelial renal tubular cell casts.
Time frame: From Baseline up to Study Week 24 of Part 1
Number of Participants With a Positive Urine Microscopy Parameters Any Time Post-Baseline During Part 2
Urine microscopy included Red Blood Cell (RBC) casts, white blood cell (WBC) casts, and epithelial renal tubular cell casts. Urine microscopy data was reviewed by the Medical Monitor in order to classify the results as positive or negative. The nmber of participants with positive finding at Baseline and at anytime post-Baseline (Post-BL) were reported. Baseline was defined as the value obtained at the first visit before treatment (Pre-trt). A positive result indicated if the result was positive for at least one of RBC casts, WBC casts, or epithelial renal tubular cell casts.
Time frame: From Baseline and post-Baseline up to Study Week 7 of Part 2
Number of Participants With a Positive Urine Microscopy Parameters Any Time Post-Baseline During Part 2/3
Urine microscopy included Red Blood Cell (RBC) casts, white blood cell (WBC) casts, and epithelial renal tubular cell casts. Urine microscopy data was reviewed by the Medical Monitor in order to classify the results as positive or negative. The number of participants with positive finding at Baseline and at anytime post-Baseline (Post-BL) were reported. Baseline was defined as the value obtained at the first visit before treatment (Pre-trt). A positive result indicated if the result was positive for at least one of RBC casts, WBC casts, or epithelial renal tubular cell casts. Participants randomized to receive eltrombopag for 7 weeks in Part 2 continued receiving eltrombopag for an additional 17 weeks in Part 2/3 (for a total of 24 weeks of treatment) up to Study Week 24. Participants randomized to receive placebo for 7 weeks in Part 2, received 24 weeks of eltrombopag in Part 2/3 (for a total of 24 weeks of treatment) up to Study Week 31.
Time frame: From Baseline and post-Baseline up to Study Week 31 of Part 2/3
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3
Vital sign assessments included systolic blood pressure (SBP) and diastolic blood pressure (DBP) measurements that were measured before any blood draw at the following scheduled time points: Screening, Day 1, each week from Week 1 to Week 24, at each Follow-up week (Week 1-4) and the maximum post- Baseline (BL) visit. BL is defined as the value obtained on Day 1of treatment. The maximum post-BL visit (MPB) included any scheduled and unscheduled post-BL assessment. Reference ranges (RR) for SBP (mmHg) (Lower limit of normal, normal, Upper limit of normal) for Cohort 1: \<85, 85-115, \>115; for Cohort 2: \<85, 85-120,\>120; and Cohort 3: \<95, 95-135, \>135. RR for DBP (mmHg) for Cohort 1: \<45, 45-70,\>70; for Cohort 2: \<50, 50-75, \>75; and Cohort 3: \<55, 55-85, \>85.
Time frame: From Baseline through Study Week 35
Mean Respiratory Rate at Baseline and the Maximum Post-Baseline Value Recorded During the Dose-Finding Period, Part 1
Respiratory rate was measured at the following scheduled time points: Screening, Day 1, each week from Week 1 to Week 24, and at each Follow-up Weeks 1-4. Baseline is defined as the value obtained on Day 1 of treatment. The maximum post-Baseline value included any scheduled and unscheduled post-Baseline assessment.
Time frame: From Baseline through Week 24
Mean Respiratory Rate at Baseline and the Maximum Post-Baseline Value Recorded During the Randomized Period, Part 2
Respiratory rate was measured at the following scheduled time points: Screening, Day 1, each week from Week 1 to Week 24, and at each Follow-up Weeks 1-4. Baseline is defined as the value obtained on Day 1 of treatment. The maximum post-Baseline value included any scheduled and unscheduled post-Baseline assessment.
Time frame: From Week 1 to Week 7 of Part 2
Mean Respiratory Rate at Baseline and Maximum Post-Baseline Visit During Part 2/3
Respiratory rate was measured at the following scheduled time points: Screening, Day 1, each week from Week 1 to Week 24, and at each Follow-up Weeks 1-4. Baseline is defined as the value obtained on Day 1 of treatment. The maximum post-Baseline visit included any scheduled and unscheduled post-Baseline assessment. Participants randomized to receive eltrombopag for 7 weeks in Part 2 continued receiving eltrombopag for an additional 17 weeks in Part 2/3 (for a total of 24 weeks of treatment) up to Study Week 24. Participants randomized to receive placebo for 7 weeks in Part 2, received 24 weeks of eltrombopag in Part 2/3 (for a total of 24 weeks of treatment) up to Study Week 31.
Time frame: From Week 1 to Follow-up Week 4 of Part 2/3 up to Study Week 35
Mean Pulse Rate at Baseline and the Maximum Post-Baseline Visit Recorded During the Dose-Finding Period, Part 1
Pulse rate was measured at the following scheduled time points: Screening, Day 1, each week from Week 1 to Week 24, and at each Follow-up Weeks 1-4. Baseline is defined as the value obtained on Day 1 of treatment. The maximum post-Baseline (MPB) visit included any scheduled and unscheduled post-Baseline assessment..
Time frame: From Week 1 to Follow-up Week 4 of Part 1, up to Study Week 28
Mean Pulse Rate at Baseline and the Maximum Post-Baseline Visit Recorded During the Randomized Period, Part 2
Pulse rate was measured at the following scheduled time points: Screening, Day 1, each week from Week 1 to Week 24, and at each Follow-up Weeks 1-4. Baseline is defined as the value obtained on Day 1 of treatment. The maximum post-Baseline visit included any scheduled and unscheduled post-Baseline assessment.
Time frame: From Week 1 to Week 7 of Part 2
Mean Pulse Rate at Baseline and the Maximum Post-Baseline Visit Recorded During the Eltrombopag Only Period Part 2/3
Pulse rate was measured at the following scheduled time points: Screening, Day 1, each week from Week 1 to Week 24, and at each Follow-up Weeks 1-4. Baseline is defined as the value obtained on Day 1 of treatment. The maximum post-Baseline visit included any scheduled and unscheduled post-Baseline assessment. Participants randomized to receive eltrombopag for 7 weeks in Part 2 continued receiving eltrombopag for an additional 17 weeks in Part 2/3 (for a total of 24 weeks of treatment) up to Study Week 24. Participants randomized to receive placebo for 7 weeks in Part 2, received 24 weeks of eltrombopag in Part 2/3 (for a total of 24 weeks of treatment) up to Study Week 31.
Time frame: From Week 1to Follow-up Week 4 of Part 2/3, up to Study Week 35
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Dose-Finding Period, Part 1
Urinalysis parameters included: urine protein (UP), urine glucose (UG), urine ketones (UK), urine occult blood (UOB), and pH. The dipstick test gives results in a semi-quantitative manner. UP was categorized as missing (MS), no result (NR), negative (Neg), Trace, 1+, 2+, 3+ and 4+. UG results were categorized as MS, NR, Neg, normal, 5, 15(1+), 30(2+), 60(3+), 110(4+)UK parameters were categorized as as MS, NR, Neg, Trace(5), Small(15), Moderate(40), Large(80), Large(160). UOB parameters were categorized as MS, NR, Neg, 1+, 2+, 3+, Non haemolysed trace, and haemolysed trace. PH results were categorized as MS. NR, normalresult, Neg, and range of pH (from 5-9in increments of 0.5). Data for indicated parameters was reported at Baseline (BL) and Week 24 (W24). The Baseline value was the measurement taken at Day 1.
Time frame: Baseline and Week 24 of Part 1
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 7 During the Randomized Period,Part 2
Urinalysis parameters included: urine protein (UP), urine glucose (UG), urine ketones (UK), urine occult blood (UOB), and pH. The dipstick test gives results in a semi-quantitative manner. UP was categorized as missing (MS), no result (NR), negative (Neg), Trace, 1+, 2+, 3+ and 4+. UG results were categorized as MS, NR, Neg, normal, 5, 15(1+), 30(2+), 60(3+), 110(4+)UK parameters were categorized as as MS, NR, Neg, Trace(5), Small(15), Moderate(40), Large(80), Large(160). UOB parameters were categorized as MS, NR, Neg, 1+, 2+, 3+, Non haemolysed trace, and haemolysed trace. PH results were categorized as MS. NR, normalresult, Neg, and range of pH (from 5-9in increments of 0.5). Data for indicated parameters was reported at Baseline (BL) and Week 7 (W7). The Baseline value was the measurement taken at Day 1.
Time frame: Baseline and Week 7 of Part 2
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Eltrombopag Open-label Period, Part 2/3
Urinalysis parameters included: urine protein (UP), urine glucose (UG), urine ketones (UK), urine occult blood (UOB), and pH. The dipstick test gives results in a semi-quantitative manner. UP was categorized as missing (MS), no result (NR), negative (Neg), Trace, 1+, 2+, 3+ and 4+. UG results were categorized as MS, NR, Neg, normal, 5, 15(1+), 30(2+), 60(3+), 110(4+)UK parameters were categorized as as MS, NR, Neg, Trace(5), Small(15), Moderate(40), Large(80), Large(160). UOB parameters were categorized as MS, NR, Neg, 1+, 2+, 3+, Non haemolysed trace, and haemolysed trace. PH results were categorized as MS. NR, normalresult, Neg, and range of pH (from 5-9in increments of 0.5). Data for indicated parameters was reported at Baseline (BL) and Week 24 (W24). The Baseline value was the measurement taken at Day 1.
Time frame: Baseline and Week 24 of Part 2/3 up to Study Week 31
Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE) During Part 1
An adverse event (AE) is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose: results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability or incapacity, or is a congenital anomaly or birth defect. Medical or scientific judgment should be exercised in other situations.
Time frame: From Treatment + 1 day up to Week 24 of Part1
Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE) During Part 2
An adverse event (AE) is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose: results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability or incapacity, or is a congenital anomaly or birth defect. Medical or scientific judgment should be exercised in other situations.
Time frame: From Treatment + 1 day up to Week 7 of Part 2
Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE) During Part 2/3
An adverse event (AE) is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose: results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability or incapacity, or is a congenital anomaly or birth defect. Medical or scientific judgment should be exercised in other situations.
Time frame: From Treatment + 1 day up to Week 31 of Part2/3
Number of Participants With a Change in Visual Acuity and a Change Due to Worsening of Cataracts During Part 1
The visual acuity assessment was performed by an ophthalmologist or an optometrist under the guidance of an ophthalmologist. Visual acuity is defined as acuteness or clearness of vision. The number of participants with a change in visual acuity and worsening visual acuity due to cataracts since Baseline are presented for Part 1 Follow-up Visits at 3-months (FU3) and at 6-months (FU6). Change in visual acuity since Baseline is displayed under the left eye but applies to both eyes. Change in visual acuity (VA) is categorized as "yes" or "no". Change due to cataracts is categorized as "yes" or "no".
Time frame: Baseline, 3and 6-mo Follow-up of Part 1
Number of Participants With a Change in Visual Acuity and a Change Due to Worsening of Cataracts
The visual acuity assessment was performed by an ophthalmologist or an optometrist under the guidance of an ophthalmologist. Visual acuity is defined as acuteness or clearness of vision. Number of participants with a change in visual acuity and change in visual acuity due to the worsening of cataracts since Baseline are presented for Part 2/3 Follow-up Visits at 3-months (FU3) and 6-months (FU6). Change in visual acuity since Baseline is displayed under the left eye but applies to both eyes. Change in visual acuity (VA) is categorized as "yes" or "no". Change due to cataracts is categorized as "yes" or "no".
Time frame: BL, 3 and 6mo Follow-up of Part 2/3
Pediatric participants (par.) meeting eligibility criteria were enrolled into 3 cohorts depending upon age. Cohort 1 enrolled participants who were between 12 and 17 years old, Cohort 2 enrolled participants who were between 6 and 11 years old, and Cohort 3 enrolled participants who were between 1 and 5 years old.
| Milestone | Part 1 (Dose-Finding Period) Cohort 1 | Part 1 (Dose-Finding Period) Cohort 2 | Part 1 (Dose-Finding Period) Cohort 3 | Part 2 (Randomized Period) Cohort 1-Placebo | Part 2 (Randomized Period) Cohort 1- Eltrombopag | Part 2 (Randomized Period) Cohort 2-Placebo | Part 2 (Randomized Period) Cohort 2-Eltrombopag | Part 2 (Randomized Period) Cohort 3-Placebo | Part 2 (Randomized Period) Cohort 3- Eltrombopag | Part 2/3 (Eltrombopag Open-Label Period) Cohort 1 | Part 2/3 (Eltrombopag Open-Label Period) Cohort 2 | Part 2/3 (Eltrombopag Open- Label Period) Cohort 3 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 5 | 5 | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 5 | 5 | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part 1 (Dose-Finding Period) Cohort 1 | Part 1 (Dose-Finding Period) Cohort 2 | Part 1 (Dose-Finding Period) Cohort 3 | Part 2 (Randomized Period) Cohort 1-Placebo | Part 2 (Randomized Period) Cohort 1- Eltrombopag | Part 2 (Randomized Period) Cohort 2-Placebo | Part 2 (Randomized Period) Cohort 2-Eltrombopag | Part 2 (Randomized Period) Cohort 3-Placebo | Part 2 (Randomized Period) Cohort 3- Eltrombopag | Part 2/3 (Eltrombopag Open-Label Period) Cohort 1 | Part 2/3 (Eltrombopag Open-Label Period) Cohort 2 | Part 2/3 (Eltrombopag Open- Label Period) Cohort 3 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 8 | 16 | 9 | 19 | 5 | 10 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 7 | 13 | 9 | 15 | 5 | 5 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 1 | 3 | 0 | 4 | 0 | 5 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 0 | 1 | 0 | 3 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 4 | 0 | 0 | 0 |
| Withdrew: Withdrawal by parent/ guardian | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part 1 (Dose-Finding Period) Cohort 1 | Part 1 (Dose-Finding Period) Cohort 2 | Part 1 (Dose-Finding Period) Cohort 3 | Part 2 (Randomized Period) Cohort 1-Placebo | Part 2 (Randomized Period) Cohort 1- Eltrombopag | Part 2 (Randomized Period) Cohort 2-Placebo | Part 2 (Randomized Period) Cohort 2-Eltrombopag | Part 2 (Randomized Period) Cohort 3-Placebo | Part 2 (Randomized Period) Cohort 3- Eltrombopag | Part 2/3 (Eltrombopag Open-Label Period) Cohort 1 | Part 2/3 (Eltrombopag Open-Label Period) Cohort 2 | Part 2/3 (Eltrombopag Open- Label Period) Cohort 3 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 24 | 28 | 15 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 21 | 24 | 12 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 4 | 3 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 |
| Withdrew: Withdrawal by parent/guardian | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Randomized but did not receive treatment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 |
Participants who achieved a platelet count \>=50 Gi/L at least once between Day 8 and Day 43 (first 6 weeks of Part 2) in the absense of rescue treatment were reported. A 95% confidence interval was calculated by the exact binomial method.
| Percentage of Participants | Part 2 (Randomized Period) Cohort 1-Placebo | Part 2 (Randomized Period) Cohort 1- Eltrombopag | Part 2 (Randomized Period) Cohort 2-Placebo | Part 2 (Randomized Period) Cohort 2-Eltrombopag | Part 2 (Randomized Period) Cohort 3-Placebo | Part 2 (Randomized Period) Cohort 3- Eltrombopag |
|---|---|---|---|---|---|---|
| Percentage of Participants Achieving a Platelet Count >=50 Giga Cells Per Liter (Gi/L) at Least Once, Between Day 8 and Day 43 (Weeks 1 to 6) of the Randomized Period of the Study (Part 2) | 0 | 62.5 | 33.3 | 63.2 | 80.0 | 60.0 |
Sustained platelet response between the treatment groups was assessed by determining the number of participants who achieved a platelet count \>=50 Gi/L during treatment with eltrombopag in \>= 60% of assessments between Day 15 and Day 43 in the absence of rescue treatment were reported here.
| Percentage of Participants | Part 2 (Randomized Period) -Placebo | Part 2 (Randomized Period) - Eltrombopag |
|---|---|---|
| Percentage of Participants Achieving Platelet Counts >=50Gi/L During Treatment With Eltrombopag in >= 60% of Assessments Between Day 15 and Day 43 (Weeks 2 Through 6) of the Randomized Treatment Period (Part 2) | 0 | 35.6 |
The weighted mean platelet count is defined as the area under the platelet-time curve divided by the duration of the treatment (12 weeks). Based on the Analysis of Covariance (ANCOVA) model, the weighted mean platelet count is the sum of the Baseline count plus the age cohort plus the treatment. Baseline was defined as the platelet count taken on Day 1 or within 48 hours prior to the first dose of treatment.
| Gi/L | Part 2 (Randomized Period) -Placebo | Part 2 (Randomized Period) - Eltrombopag |
|---|---|---|
| Baseline | 12.2 ± 8.59 | 15.5 ± 8.03 |
| Day 43 | 30.5 ± 24.98 | 68 ± 56.78 |
The percentage of participants achieving platelet counts \>=50Gi/L at least once at any time during the 24 weeks of eltrombopag treatment were reported.
| Percentage of Participants | Part 1 (Dose-Finding Period) Cohort 1 | Part 1 (Dose-Finding Period) Cohort 2 | Part 1 (Dose-Finding Period) Cohort 3 |
|---|---|---|---|
| Percentage of Participants Achieving Platelet Counts >=50Gi/L at Any Time During the 24 Weeks of Eltrombopag Dosing During Part 1. | 80 | 80 | 60 |
The percentage of participants achieving platelet counts \>=50Gi/L at least once at any time during the 24 weeks of eltrombopag treatment during Part 2/3 of the study were reported. Participants randmoized to receive eltrombopag for 7 weeks in Part 2 continued receiving eltrombopag for an additional 17 weeks in Part 2/3 (for a total of 24 weeks of treatment) up to Study Week 24. Participants randomized to receive placebo for 7 weeks in Part 2, received 24 weeks of eltrombopag in Part 2/3 (for a total of 24 weeks of treatment) up to Study Week 31.
| Percentage of Participants | Part 2/3 (Eltrombopag Open-Label Period) Cohort 1 | Part 2/3 (Eltrombopag Open-Label Period) Cohort 2 | Part 2/3 (Eltrombopag Open-Label Period) Cohort 3 |
|---|---|---|---|
| Percentage of Participants Achieving Platelet Counts >=50 Gi/L at Any Time During the 31 Weeks of Eltrombopag Treatment During Part 2/ 3. | 75.0 | 82.1 | 86.7 |
The area under the concentration-time curve over the dosing interval (AUC0-t) data was collected to estimate primary model-based PK parameters. PK samples were collected within 3 hours prior to dosing and 2, 4, 6, 8 and 24 hours after dosing. Doses were normalized to 50mg for comparison. PK samples were collected at each on-treatment visit during Part 1, Part 2, and Part 2/3. The concentration data were pooled across visits to identify population PK and variability parameter estimates and covariate effects. AUC(0-t) is defined as the area under the concentration-time curve over the dosing interval. From the final model, a single value of AUC(0-t) was estimated for each subject, and geometric mean (95% CI) values are presented for each cohort for a 50mg dose.
| Microgram*hour per milliliter (ug*h/mL) | Eltrombopag Cohort 1- 12-17 Years | Eltrombopag Cohort 2 - 6-11 Years | Eltrombopag Cohort 3 - 1-5 Years |
|---|---|---|---|
| Population Pharmacokinetic (PK) Assessment for Eltrombopag for AUC(0-t) During Part 1, 2, and 2/3. | 101 (87.1 to 117) | 132 (114 to 152) | 142 (117 to 173) |
The maximum observed concentration (Cmax) and the concentration at the end of the dosing interval (Ct) data were collected to estimate primary model-based PK parameters. PK samples were collected within 3 hours prior to dosing and 2, 4, 6, 8 and 24 hours after dosing. Doses were normalized to 50mg for comparison. PK samples were collected at each on-treatment visit during Part 1, Part 2, and Part 2/3. The concentration data were pooled across visits to identify population PK and variability parameter estimates and covariate effects. From the final model, a single value of Cmax and Ct were estimated for each subject, and geometric mean (95% CI) values are presented for each cohort for a 50mg dose.
| micrograms per milliliter (ug/mL) | Eltrombopag Cohort 1- 12-17 Years | Eltrombopag Cohort 2 - 6-11 Years | Eltrombopag Cohort 3 - 1-5 Years |
|---|---|---|---|
| Cmax | 6.65 (5.87 to 7.53) | 9.19 (8.18 to 10.3) | 10.7 (9.24 to 12.5) |
| Ct | 2.42 (1.97 to 2.98) | 2.95 (2.41 to 3.60) | 2.91 (2.14 to 3.96) |
The time to maximum concentration (tmax) was collected to estimate primary model-based PK parameters. PK samples were collected within 3 hours prior to dosing and 2, 4, 6, 8 and 24 hours after dosing. PK samples were collected at each on-treatment visit during Part 1, Part 2, and Part 2/3. The concentration data were pooled across visits to identify population PK and variability parameter estimates and covariate effects. From the final model, a single value of tmax was estimated for each subject, and geometric mean (95% CI) values are presented for each cohort for a 50mg dose.
| hour (hr) | Eltrombopag Cohort 1- 12-17 Years | Eltrombopag Cohort 2 - 6-11 Years | Eltrombopag Cohort 3 - 1-5 Years |
|---|---|---|---|
| Population Pharmacokinetic (PK) Assessments for Eltrombopag for Tmax During Part 1, 2, and 2/3 | 4.0 (2.0 to 6.0) | 4.0 (2.0 to 6.0) | 2.0 (2.0 to 4.0) |
The apparent plasma clearance following oral dosing of eltrombopag (CL/F) was collected to estimate primary model-based PK parameters. PK samples were collected within 3 hours prior to dosing and 2, 4, 6, 8 and 24 hours after dosing. PK samples were collected at each on-treatment visit during Part 1, Part 2, and Part 2/3. The concentration data were pooled across visits to identify population PK and variability parameter estimates and covariate effects. From the final model, a single value of CL/F was estimated for each subject, and geometric mean (95% CI) values are presented for each cohort for a 50mg dose.
| liter per hour (L/hr) | Eltrombopag Cohort 1- 12-17 Years | Eltrombopag Cohort 2 - 6-11 Years | Eltrombopag Cohort 3 - 1-5 Years |
|---|---|---|---|
| Population Pharmacokinetic (PK) Assessments for Eltrombopag for CL/F During Part 1, 2, and 2/3 | 0.50 (0.43 to 0.57) | 0.38 (0.33 to 0.44) | 0.25 (0.20 to 0.30) |
The maximum duration for which a participant continuously maintained a platelet count \>=50 Gi/L in the absence of rescue treatment was calculated and summarized during the 24 weeks of eltrombopag treatment in Part 2. Participants with non-weekly assessments were assumed to have maintained a positive response for each week between two assessments that had positive responses. If a particpant achieved a positive response at an assessment and then achieved a negative response at the next assessment, then it was assumed that the participant had achieved a positive response for one day. Excludes periods from initiation of rescue medication until platelet count falls to below 50Gi/L, irrespective of platelet count
| Weeks | Part 2 (Randomized Period) Cohort 1-Placebo | Part 2 (Randomized Period) Cohort 1- Eltrombopag | Part 2 (Randomized Period) Cohort 2-Placebo | Part 2 (Randomized Period) Cohort 2-Eltrombopag | Part 2 (Randomized Period) Cohort 3-Placebo | Part 2 (Randomized Period) Cohort 3- Eltrombopag |
|---|---|---|---|---|---|---|
| Maximum Duration for Which a Participant Continuously Maintained a Platelet Count of >=50 Gi/L During the 7 Weeks of Eltrombopag Treatment in Part 2 | 0.0 (0 to 0) | 1.0 (0 to 5) | 0.0 (0 to 2) | 2.0 (0 to 6) | 1.0 (0 to 2) | 1.0 (0 to 6) |
The maximum duration for which a participant continuously maintained a platelet count \>=50 Gi/L in the absence of rescue treatment was calculated and summarized during the 24 weeks of eltrombopag treatment in Part 2/3. Participants with non-weekly assessments were assumed to have maintained a positive response for each week between two assessments that had positive responses. If a particpant achieved a positive response at an assessment and then achieved a negative response at the next assessment, then it was assumed that the participant had achieved a positive response for one day. Participants randmoized to receive eltrombopag for 7 weeks in Part 2 continued receiving eltrombopag for an additional 17 weeks in Part 2/3 (for a total of 24 weeks of treatment) up to Study Week 24. Participants randomized to receive placebo for 7 weeks in Part 2, received 24 weeks of eltrombopag in Part 2/3 (for a total of 24 weeks of treatment) up to Study Week 31.
| Weeks | Part 2/3 (Eltrombopag Open-Label Period) Cohort 1 | Part 2/3 (Eltrombopag Open-Label Period) Cohort 2 | Part 2/3 (Eltrombopag Open-Label Period) Cohort 3 |
|---|---|---|---|
| Maximum Duration for Which a Participant Continuously Maintained a Platelet Count of >=50 Gi/L During the 24 Weeks of Eltrombopag Treatment in Part 2/ 3 | 2.0 (0 to 23) | 8.0 (0 to 24) | 4.0 (0 to 24) |
The participants who discontinued (dis) or had a sustained reduction (red) of a Baseline (BL) ITP medication for at least one day during the period of Day 1 of Part 1 to the last dose of study medication +1 day are reported. The denominator is the number of subjects taking an ITP medication at baseline. For participants in Part 1, Baseline is defined as Day 1 of Part 1. A sustained reduction is defined as reduction for 4 weeks or more. An attempted red or dis is a decrease in the dose or frequency from the BL dose or frequency of an ITP medication for at least one day during the period Part 1 Day 1 to the last dose of study medication + 1 day.
| Percentage of Participants | Part 1 (Dose-Finding Period) Cohort 1 | Part 1 (Dose-Finding Period) Cohort 2 | Part 1 (Dose-Finding Period) Cohort 3 |
|---|---|---|---|
| Taking an ITP medication at BL | 0 | 20.0 | 0 |
| Attempted red or dis | 0 | 100.0 | 0 |
| Permanent red or dis of all BL ITP mediation | 0 | 100.0 | 0 |
| Permanent red or dis at least 1 BL ITP medcation | 0 | 100.0 | 0 |
Participants who discontinued (dis) or had a sustained reduction (red) of a Baseline (BL) ITP medication for at least one day during the period of Day 1 of Part 2/3 to the last dose of study medication +1 day are reported. The denominator is the number of subjects taking an ITP medication at baseline. For participants randomized to placebo in Part 2, BL is defined as Week 7 of Part 2. For participants randomized to eltrombopag in Part 2, BL is defined as Day 1 of Part 2. A sustained reduction is defined as reduction for 4 weeks or more. An attempted reduction or discontinuation is a decrease in the dose or frequency from the BL dose or frequency of an ITP medication for at least one day during the period Part 2/3 Day 1 to the last dose of study medication + 1 day.
| Percentage of Participants | Part 2/3 (Eltrombopag Open-Label Period) Cohort 1 | Part 2/3 (Eltrombopag Open-Label Period) Cohort 2 | Part 2/3 (Eltrombopag Open-Label Period) Cohort 3 |
|---|---|---|---|
| Taking an ITP medication at BL | 25.0 | 17.9 | 13.3 |
| Attempted red or dis | 66.7 | 20.0 | 100.0 |
| Permanent (perm) dis of all BL ITP medication(med) | 16.7 | 20.0 | 50.0 |
| Perm dis at least 1 BL ITP med | 33.3 | 20.0 | 50.0 |
| Perm dis all BL ITP med taken prior to Part 2/3 | 0 | 40.0 | 0 |
Rescue treatment was defined as either a new immune (idiopathic) thrombocytopenic purpura (ITP) medication, an increase in the dose of a concomitant ITP medication from Baseline, a platelet transfusion, or a splenectomy. For particpants randomized to placebo in Part 2, Baseline is defined as Week 7 of Part 2. For participants randomized to eltrombopag in Part 2, Baseline is defined as Day 1 of Part 2. Participants randmoized to receive eltrombopag for 7 weeks in Part 2 continued receiving eltrombopag for an additional 17 weeks in Part 2/3 (for a total of 24 weeks of treatment) up to Study Week 24. Participants randomized to receive placebo for 7 weeks in Part 2, received 24 weeks of eltrombopag in Part 2/3 (for a total of 24 weeks of treatment) up to Study Week 31.
| Participants | Part 2/3 (Eltrombopag Open-Label Period) Cohort 1 | Part 2/3 (Eltrombopag Open-Label Period) Cohort 2 | Part 2/3 (Eltrombopag Open-Label Period) Cohort 3 |
|---|---|---|---|
| New ITP Medication | 8 | 4 | 4 |
| Increase concomitant ITP medication from Baseline | 1 | 0 | 0 |
| Platelet transfusion | 0 | 0 | 0 |
| Splenectomy | 0 | 0 | 0 |
The KIT questionnaire measures the impact on the quality of life determined by the participant and the guardian by self reported outcomes at Baseline or the Screening Visit, after 6 weeks of treatment, after 12 weeks of treatment and at the end of treatment or withdrawal from the study. The KIT total score is calculated from the scores of each of the individual questions from Q1 - Q26 (excluding any answer that is 'Not applicable'). The code list used for the individual question scores is: 1 = never, 2 = seldom, 3 = sometimes, 4 = often, 5 = always and 9 = not applicable. The range of values the total score can take is 0 (worst) to 100 (best). For subjects under the age of six, the family questionnaire (parental proxy) has been used.
| Score on scale | Part 1 (Dose-Finding Period) Cohort 1 | Part 1 (Dose-Finding Period) Cohort 2 | Part 1 (Dose-Finding Period) Cohort 3 |
|---|---|---|---|
| Baseline, n=5, 5, 5 | 73.18 ± 15.743 | 53.95 ± 16.534 | 74.80 ± 17.199 |
| Week 6, n=4, 5, 5 | 82.84 ± 9.131 | 61.57 ± 13.664 | 71.54 ± 14.798 |
| Week 12, n=4, 4, 4 | 84.14 ± 11.712 | 66.43 ± 12.349 | 65.58 ± 17.887 |
| Week 24, n= 3, 4, 3 | 76.38 ± 20.228 | 82.50 ± 15.995 | 78.87 ± 12.056 |
The KIT questionnaire measures the impact on the quality of life determined by the participant and the guardian by self reported outcomes at Baseline or the Screening Visit, after 6 weeks of treatment or withdrawal from the study. The KIT total score is calculated from the scores of each of the individual questions from Q1 - Q26 (excluding any answer that is 'Not applicable'). The code list used for the individual question scores is: 1 = never, 2 = seldom, 3 = sometimes, 4 = often, 5 = always and 9 = not applicable. The range of values the total score can take is 0 (worst) to 100 (best). For subjects under the age of six, the family questionnaire (parental proxy) has been used.
| Score on scale | Part 2 (Randomized Period) Cohort 1-Placebo | Part 2 (Randomized Period) Cohort 1- Eltrombopag | Part 2 (Randomized Period) Cohort 2-Placebo | Part 2 (Randomized Period) Cohort 2-Eltrombopag | Part 2 (Randomized Period) Cohort 3-Placebo | Part 2 (Randomized Period) Cohort 3- Eltrombopag |
|---|---|---|---|---|---|---|
| Baseline, n=6, 11, 9, 10, 2, 8 | 83.94 ± 8.674 | 76.84 ± 15.049 | 71.05 ± 19.581 | 66.36 ± 17.321 | 82.61 ± 7.686 | 78.23 ± 9.575 |
| Week 6, n= 8,11,7,13, 5, 9 | 79.46 ± 10.971 | 79.46 ± 13.899 | 74.65 ± 20.968 | 80.16 ± 13.776 | 88.01 ± 3.333 | 80.85 ± 15.082 |
The KIT questionnaire measures the impact on the quality of life determined by the participant and the guardian by self reported outcomes at Baseline or the Screening Visit, after 6 weeks of treatment, after 12 weeks of treatment and at the end of treatment or withdrawal from the study. The KIT total score is calculated from the scores of each of the individual questions from Q1 - Q26 (excluding any answer that is 'Not applicable'). The code list used for the individual question scores is: 1=never, 2=seldom, 3=sometimes, 4=often, 5=always and 9=not applicable. The range of values the total score can take is 0 (worst) to 100 (best). For subjects under the age of six, the family questionnaire (parental proxy) has been used.
| Score on scale | Part 2/3 (Eltrombopag Period) Cohort 1 | Part 2/3 (Eltrombopag Period) Cohort 2 | Part 2/3 (Eltrombopag Period) Cohort 3 |
|---|---|---|---|
| Baseline, n=17, 18, 10 | 79.34 ± 13.315 | 70.59 ± 16.237 | 79.10 ± 9.016 |
| Week 6, n=11, 13, 9 | 79.46 ± 13.899 | 80.16 ± 13.776 | 80.85 ± 15.082 |
| Week 12, n=9, 7, 2 | 84.25 ± 7.531 | 76.48 ± 19.948 | 88.10 ± 11.166 |
| Week 24, n=17, 11, 8 | 82.16 ± 16.926 | 83.93 ± 13.327 | 77.93 ± 22.971 |
The WHO Bleeding Scale is a measure of bleeding severity with the following grades: Grade 0 = no bleeding, Grade 1 = petechiae, Grade 2 = mild blood loss, Grade 3 = gross bleeding and Grade 4 = debilitating blood loss. The WHO grades were dichotomized into the following categories: no bleeding=Grade 0; any bleeding=Grades 1 to 4; no clinically significant bleeding=Grades 0 to 1; clinically significant bleeding=Grades 2 to 4. For participants randomized to Placebo in Part 2, Baseline defined as Week 7 of Part 2. For participants randomized to Eltrombopag in Part 2, Baseline defined as Day 1 of Part 2.
| Participants | Part 2 (Randomized Period) Cohort 1-Placebo | Part 2 (Randomized Period) Cohort 1- Eltrombopag | Part 2 (Randomized Period) Cohort 2-Placebo | Part 2 (Randomized Period) Cohort 2-Eltrombopag | Part 2 (Randomized Period) Cohort 3-Placebo | Part 2 (Randomized Period) Cohort 3- Eltrombopag |
|---|---|---|---|---|---|---|
| Baseline, Grades 1-4, n=8, 16, 9, 19, 5, 10 | 6 | 16 | 7 | 11 | 5 | 8 |
| Baseline, Grades 0-1, n=8, 16, 9, 19, 5, 10 | 6 | 13 | 6 | 17 | 4 | 6 |
| Baseline, Grades 2-4, n=8, 16, 9, 19, 5, 10 | 2 | 3 | 3 | 2 | 1 | 4 |
| Week 1, Grades 1-4, n=8, 16, 9, 17, 5, 10 | 7 | 9 | 6 | 7 | 3 | 7 |
| Week 1, Grades 0-1, n=8, 16, 9, 17, 5, 10 | 3 | 14 | 6 | 17 | 5 | 5 |
| Week 1, Grades 2-4, n=8, 16, 9, 17, 5, 10 | 5 | 2 | 3 | 0 | 0 | 5 |
| Week 2, Grades 1-4, n=8, 16, 9, 17, 5, 10 | 7 | 11 | 6 | 6 | 2 | 5 |
| Week 2, Grades 0-1, n=8, 16, 9, 17, 5, 10 | 5 | 13 | 7 | 16 | 3 | 7 |
| Week 2, Grades 2-4, n=8, 16, 9, 17, 5, 10 | 3 | 3 | 2 | 1 | 2 | 3 |
| Week 3, Grades 1-4, n=8, 16, 9, 16, 5, 9 | 6 | 10 | 7 | 6 | 2 | 5 |
| Week 3, Grades 0-1, n=8, 16, 9, 16, 5, 9 | 5 | 14 | 7 | 14 | 3 | 7 |
| Week 3, Grades 2-4, n=8, 16, 9, 16, 5, 9 | 3 | 2 | 2 | 2 | 2 | 2 |
| Week 4, Grades 1-4, n=8, 16, 9, 17, 5, 9 | 6 | 7 | 7 | 7 | 2 | 6 |
| Week 4, Grades 0-1, n=8, 16, 9, 17, 5, 9 | 6 | 16 | 8 | 17 | 3 | 7 |
| Week 4, Grades 2-4, n=8, 16, 9, 17, 5, 9 | 2 | 0 | 1 | 0 | 2 | 2 |
| Week 5, Grades 1-4, n=8, 16, 9, 16, 5, 9 | 6 | 8 | 7 | 3 | 4 | 5 |
| Week 5, Grades 0-1, n=8, 16, 9, 16, 5, 9 | 4 | 14 | 8 | 16 | 4 | 8 |
| Week 5, Grades 2-4, n=8, 16, 9, 16, 5, 9 | 4 | 2 | 1 | 0 | 1 | 1 |
| Week 6, Grades 1-4, n=8, 16, 9, 17, 5, 9 | 5 | 2 | 7 | 4 | 4 | 4 |
| Week 6, Grades 0-1, n=8, 16, 9, 17, 5, 9 | 7 | 16 | 7 | 16 | 4 | 9 |
| Week 6, Grades 2-4, n=8, 16, 9, 17, 5, 9 | 1 | 0 | 2 | 1 | 1 | 0 |
| Week 7, Grades 1-4, n=8, 16, 9, 17, 5, 9 | 7 | 5 | 7 | 5 | 4 | 4 |
| Week 7, Grades 0-1, n=8, 16, 9, 17, 5, 9 | 4 | 15 | 8 | 16 | 3 | 7 |
| Week 7, Grades 2-4, n=8, 16, 9, 17, 5, 9 | 4 | 1 | 1 | 1 | 2 | 2 |
The WHO Bleeding Scale is a measure of bleeding severity with the following grades: Grade 0 = no bleeding, Grade 1 = petechiae, Grade 2 = mild blood loss, Grade 3 = gross bleeding and Grade 4 = debilitating blood loss. The WHO grades were dichotomized into the following categories: no bleeding=Grade 0; any bleeding=Grades 1 to 4; no clinically significant bleeding=Grades 0 to 1; clinically significant bleeding=Grades 2 to 4. For participants randomized to Placebo in Part 2, Baseline defined as Week 7 of Part 2. For participants randomized to Eltrombopag in Part 2, Baseline defined as Day 1 of Part 2.
| Participants | Part 2/ 3 (Eltrombopag Period) Cohort 1 | Part 2/3 (Eltrombopag Period) Cohort 2 | Part 2/3 (Eltrombopag Period) Cohort 3 |
|---|---|---|---|
| Baseline, Grades 1-4, n=24, 28, 15 | 23 | 18 | 12 |
| Baseline, Grades 0-1, n=24, 28, 15 | 17 | 25 | 9 |
| Baseline, Grades 2-4, n=24, 28, 15 | 7 | 3 | 6 |
| Week 1, Grades 1-4, n=24, 26, 15 | 14 | 13 | 9 |
| Week 1, Grades 0-1, n=24, 26, 15 | 20 | 24 | 9 |
| Week 1, Grades 2-4, n=24, 26, 15 | 4 | 2 | 6 |
| Week 2, Grades 1-4, n=24, 26, 14 | 15 | 12 | 8 |
| Week 2, Grades 0-1, n=24, 26, 14 | 21 | 23 | 10 |
| Week 2, Grades 2-4, n=24, 26, 14 | 3 | 3 | 4 |
| Week 3, Grades 1-4, n=24, 25, 14 | 13 | 9 | 6 |
| Week 3, Grades 0-1, n=24, 25, 14 | 21 | 23 | 12 |
| Week 3, Grades 2-4, n=24, 25, 14 | 3 | 2 | 2 |
| Week 4, Grades 1-4, n=24, 26, 13 | 10 | 11 | 8 |
| Week 4, Grades 0-1, n=24, 26, 13 | 24 | 26 | 10 |
| Week 4, Grades 2-4, n=24, 26, 13 | 0 | 0 | 3 |
| Week 5, Grades 1-4, n=24, 24, 13 | 11 | 4 | 9 |
| Week 5, Grades 0-1, n=24, 24, 13 | 21 | 24 | 12 |
| Week 5, Grades 2-4, n=24, 24, 13 | 3 | 0 | 1 |
| Week 6, Grades 1-4, n=23, 24, 12 | 6 | 6 | 4 |
| Week 6, Grades 0-1, n=23, 24, 12 | 23 | 22 | 12 |
| Week 6, Grades 2-4, n=23, 24, 12 | 0 | 2 | 0 |
| Week 7, Grades 1-4, n=22, 25, 14 | 8 | 7 | 4 |
| Week 7, Grades 0-1, n=22, 25, 14 | 20 | 24 | 12 |
| Week 7, Grades 2-4, n=22, 25, 14 | 2 | 1 | 2 |
| Week 8, Grades 1-4, n=19, 21, 11 | 10 | 6 | 5 |
| Week 8, Grades 0-1, n=19, 21, 11 | 19 | 19 | 9 |
| Week 8, Grades 2-4, n=19, 21, 11 | 0 | 2 | 2 |
| Week 9, Grades 1-4, n=17, 16, 12 | 8 | 5 | 6 |
| Week 9, Grades 0-1, n=17, 16, 12 | 13 | 16 | 10 |
| Week 9, Grades 2-4, n=17, 16, 12 | 4 | 0 | 2 |
| Week 10, Grades 1-4, n=16, 14, 11 | 5 | 5 | 7 |
| Week 10, Grades 0-1, n=16, 14, 11 | 16 | 12 | 11 |
| Week 10, Grades 2-4, n=16, 14, 11 | 0 | 2 | 0 |
| Week 11, Grades 1-4, n=16, 15, 12 | 15 | 5 | 7 |
| Week 11, Grades 0-1, n=16, 15, 12 | 16 | 13 | 10 |
| Week 11, Grades 2-4, n=16, 15, 12 | 0 | 2 | 2 |
| Week 12, Grades 1-4, n=19, 16, 9 | 6 | 7 | 4 |
| Week 12, Grades 0-1, n=19, 16, 9 | 18 | 14 | 7 |
| Week 12, Grades 2-4, n=19, 16, 9 | 1 | 2 | 2 |
| Week 13, Grades 1-4, n=12, 14, 10 | 6 | 5 | 6 |
| Week 13, Grades 0-1, n=12, 14, 10 | 12 | 13 | 10 |
| Week 13, Grades 2-4, n=12, 14, 10 | 0 | 1 | 0 |
| Week 14, Grades 1-4, n=15, 11, 17 | 3 | 2 | 3 |
| Week 14, Grades 0-1, n=15, 11, 17 | 15 | 11 | 5 |
| Week 14, Grades 2-4, n=15, 11, 17 | 0 | 0 | 2 |
| Week 15, Grades 1-4, n=12, 14, 6 | 6 | 3 | 3 |
| Week 15, Grades 0-1, n=12, 14, 6 | 10 | 14 | 5 |
| Week 15, Grades 2-4, n=12, 14, 6 | 2 | 0 | 1 |
| Week 16, Grades 1-4, n=17, 15, 9 | 7 | 8 | 4 |
| Week 16, Grades 0-1, n=17, 15, 9 | 17 | 14 | 9 |
| Week 16, Grades 2-4, n=17, 15, 9 | 0 | 1 | 0 |
| Week 17, Grades 1-4, n=13, 11, 5 | 5 | 3 | 4 |
| Week 17, Grades 0-1, n=13, 11, 5 | 13 | 11 | 5 |
| Week 17, Grades 2-4, n=13, 11, 5 | 0 | 0 | 0 |
| Week 18, Grades 1-4, n=16, 12 ,4 | 3 | 2 | 3 |
| Week 18, Grades 0-1, n=16, 12 ,4 | 16 | 11 | 4 |
| Week 18, Grades 2-4, n=16, 12 ,4 | 0 | 1 | 0 |
| Week 19, Grades 1-4, n=14, 15, 7 | 3 | 4 | 1 |
| Week 19, Grades 0-1, n=14, 15, 7 | 14 | 14 | 7 |
| Week 19, Grades 2-4, n=14, 15, 7 | 0 | 1 | 0 |
| Week 20, Grades 1-4, n=13, 13, 8 | 2 | 3 | 2 |
| Week 20, Grades 0-1, n=13, 13, 8 | 13 | 13 | 6 |
| Week 20, Grades 2-4, n=13, 13, 8 | 0 | 0 | 2 |
| Week 21, Grades 1-4, n=4, 10, 3 | 1 | 0 | 0 |
| Week 21, Grades 0-1, n=4, 10, 3 | 4 | 10 | 3 |
| Week 21, Grades 2-4, n=4, 10, 3 | 0 | 0 | 0 |
| Week 22, Grades 1-4, n=12,7, 5 | 2 | 2 | 2 |
| Week 22 Grades 0-1, n=12,7, 5 | 12 | 6 | 5 |
| Week 22 Grades 2-4, n=12,7, 5 | 0 | 1 | 0 |
| Week 23, Grades 1-4, n=8, 7,6 | 1 | 1 | 2 |
| Week 23, Grades 0-1, n=8, 7,6 | 8 | 7 | 6 |
| Week 23, Grades 2-4, n=8, 7,6 | 0 | 0 | 0 |
| Week 24, Grades 1-4, n=23, 24, 13 | 5 | 5 | 4 |
| Week 24, Grades 0-1, n=23, 14, 13 | 21 | 24 | 12 |
| Week 24, Grades 2-4, n=23, 14, 13 | 2 | 0 | 1 |
| Follow Up Week 1, Grades 1-4, n=8, 5, 3 | 5 | 1 | 3 |
| Follow Up Week 1, Grades 0-1, n=8, 5, 3 | 8 | 4 | 2 |
| Follow Up Week 1, Grades 2-4, n=8, 5, 3 | 0 | 1 | 1 |
| Follow Up Week 2, Grades 1-4, n=7, 7, 7 | 2 | 6 | 2 |
| Follow Up Week 2, Grades 0-1, n=7, 7, 7 | 7 | 6 | 6 |
| Follow Up Week 2, Grades 2-4, n=7, 7, 7 | 0 | 1 | 1 |
| Follow Up Week 3, Grades 1-4, n=5, 5, 5 | 1 | 2 | 4 |
| Follow Up Week 3, Grades 0-1, n=5, 5, 5 | 5 | 5 | 4 |
| Follow Up Week 3, Grades 2-4, n=5, 5, 5 | 0 | 0 | 1 |
| Follow Up Week 4, Grades 1-4, n=9, 14, 8 | 5 | 4 | 3 |
| Follow Up Week 4, Grades 0-1, n=9, 14, 8 | 8 | 13 | 7 |
| Follow Up Week 4, Grades 2-4, n=9, 14, 8 | 1 | 1 | 1 |
| Any Follow Up Visit, Grades 1, n=15, 18, 10 | 7 | 10 | 5 |
| Any Follow Up Visit, Grades 0-1, n=15, 18, 10 | 15 | 18 | 9 |
| Any Follow Up Visit, Grades 2-4, n=15, 18, 10 | 1 | 3 | 3 |
Clinical chemistry parameters included: aspartate amino transferase (AST, reference range \[RR\]: 0-38 International Units per Liter \[IU/L\]), alkaline phosphatase (ALP: RR: 50 - 375 IU/L), total bilirubin (RR: 3.42 - 22.23 micromoles \[umol\]/L), albumin grams \[g/L\], alanine amino transferase (ALT, RR: 5-30 IU/L), prothrombin international normalized ratio (PT INR, RR-0.9 - 1.2), activated partial thromboplastin time (APTT, RR: 24.2 - 32.9 seconds), glucose (RR: 4.107- 6.55018 millimoles \[mmol\]/L), potassium (3 - 5 mmol/L), and sodium (135 - 143 mmol/L). Baseline values were obtained at Day 1. The number of participants with the indicated clinical chemistry data outside of the reference range (with high and low) any time post-Baseline are presented. Anytime post-Baseline assesments included any scheduled and unscheduled post-Baseline assessment
| Participants | Part 1 (Dose-Finding Period) | Part 2 (Randomized Period) -Placebo | Part 2 (Randomized Period) - Eltrombopag | Part 2/3 (Eltrombopag Open-Label Period) |
|---|---|---|---|---|
| AST high, n=15, 21, 44, 65 | 5 | 4 | 7 | 17 |
| AST low, n=15, 21, 44, 65 | 1 | 1 | 3 | 7 |
| ALT, high, n= 15, 21, 44, 65 | 2 | 3 | 3 | 14 |
| ALT, low, n= 15, 21, 44, 65 | 2 | 3 | 4 | 11 |
| Total Bilirubin, high, n=15, 21, 44, 65 | 5 | 2 | 2 | 9 |
| Total Bilirubin, low, n=15, 21, 44, 65 | 6 | 0 | 16 | 31 |
| Direct Bilirubin, high, n=10, 16, 34, 55 | 0 | 1 | 1 | 3 |
| Direct Bilirubin, low, n=10, 16, 34, 55 | 1 | 0 | 6 | 8 |
| Albumin, high, n=15, 21, 24, 65 | 3 | 3 | 2 | 9 |
| Albumin, low, n=15, 21, 24, 65 | 1 | 3 | 5 | 11 |
| ALP, high, n=15, 21, 24, 65 | 4 | 1 | 6 | 13 |
| ALP, low, n=15, 21, 24, 65 | 2 | 2 | 4 | 11 |
| PT INR, high, n=15, 20, 42, 64 | 2 | 1 | 4 | 12 |
| PT INR, low, n=15, 20, 42, 64 | 0 | 0 | 0 | 1 |
| PT, high, n=13, 20, 36, 61 | 5 | 5 | 8 | 24 |
| PT, low, n=13, 20, 36, 61 | 0 | 1 | 0 | 3 |
| PTT, high, n=15, 21, 41, 63 | 4 | 2 | 1 | 11 |
| PTT, low, n=15, 21, 41, 63 | 0 | 1 | 1 | 9 |
| Glucose, high, n=15, 21, 44, 65 | 5 | 5 | 7 | 27 |
| Glucose, low, n=15, 21, 44, 65 | 7 | 6 | 16 | 29 |
| Potassium, high, n=15, 21, 44, 65 | 7 | 0 | 3 | 9 |
| Potassium, low, n=15, 21, 44, 65, | 3 | 4 | 8 | 14 |
| Sodium, high, n=15, 21, 44, 65 | 2 | 1 | 2 | 6 |
| Sodium, low, n=15, 21, 44, 65 | 2 | 1 | 4 | 9 |
Hematology parameters included: erythrocytes (RR: 4.2 - 6.1 teragrams per liter \[TI/L\]), hemoglobin (RR: 125 - 165 g/L), hematocrit (RR: 0.36 - 0.46), platelets (RR: 170 - 430 gigagrams per liter \[GI/L\]), mean platelet volume (MPV, RR: 4 - 14 femotoliter \[fL\]), leukocytes (RR: 3.4 - 11.2 GI/L), total neutrophils (RR: 2.1 - 4.9 GI/L), lymphocytes (RR: 1.4 - 2.9 GI/L), monocytes (RR: 0.2 - 0.9 GI/L), eosinophils (RR: 0.2 - 0.7 GI/L), and basophils (RR: 0.02 - 0.12 GI/L). Baseline values were obtained at Day 1. The number of participants with the indicated hematology parameters data outside of the reference range (with high and low) any time post-baseline are presented. Anytime post-Baseline assesments included any scheduled and unscheduled post-Baseline assessment
| Participants | Part 1 (Dose-Finding Period) | Part 2 (Randomized Period) -Placebo | Part 2 (Randomized Period) - Eltrombopag | Part 2/ 3 (Eltrombopag Open-Label Period) |
|---|---|---|---|---|
| Erythrocytes high, n=15, 21, 44, 65 | 5 | 0 | 7 | 15 |
| Erythrocytes low, n=15, 21, 44, 65 | 2 | 8 | 13 | 24 |
| Hemoglobin, high, n= 15, 21, 44, 65 | 2 | 2 | 2 | 8 |
| Hemoglobin low, n= 15, 21, 44, 65 | 10 | 5 | 15 | 32 |
| Hematocrit, high, n=15, 21, 44, 65 | 1 | 0 | 0 | 5 |
| Hematocrit, low, n=15, 21, 44, 65 | 10 | 11 | 22 | 39 |
| Platelets, high, n=15, 21, 44, 65 | 9 | 0 | 6 | 14 |
| Platelets, low, n=15, 21, 44, 65 | 15 | 21 | 44 | 65 |
| Leukocytes, high, n=15, 21, 44, 65 | 6 | 5 | 8 | 27 |
| Leukocytes, low, n=15, 21, 44, 65 | 4 | 5 | 10 | 19 |
| Neutrophils, high, n=15, 21, 44, 65 | 7 | 5 | 11 | 33 |
| Neutrophils, low, n=15, 21, 44, 65 | 3 | 4 | 10 | 21 |
| Lymphocytes, high, n=15, 21, 44, 65 | 1 | 3 | 5 | 11 |
| Lymphocytes, low, n=15, 21, 44, 65 | 5 | 6 | 10 | 25 |
| Monocytes, high, n=15, 21, 44, 65 | 3 | 3 | 7 | 15 |
| Monocytes, low, n=15, 21, 44, 65 | 4 | 7 | 10 | 23 |
| Eosinophils, high, n=15, 21, 44, 65 | 5 | 3 | 11 | 24 |
| Eosinophils, low, n=15, 21, 44, 65 | 4 | 2 | 5 | 9 |
| Basophils, high, n=15, 21, 44, 65 | 6 | 5 | 10 | 20 |
| Basophils, low, n=15, 21, 44, 65 | 2 | 0 | 1 | 1 |
| Mean Platelet Volume, high, n=12, 17, 40, 59 | 10 | 10 | 23 | 47 |
| Mean Platelet Volume, low, n=12, 17, 40, 59 | 4 | 6 | 10 | 16 |
Renal parameters included: creatinine (RR: 44.2 - 88.4 umol/L), creatinine clearance derived (RR: 89.0 - 165.0 milliliter per minute \[ ml/min\]), protein/creatinine (RR: 0.113- 18.0992 microgram per millimoles \[mg/mmol\]), and urea (RR: 1.785- 8.925 mmol/L). Baseline values were obtained at Day 1. The number of participants with the indicated renal parameters data outside the reference range (with high and low) any time post-Baseline are presented. Anytime post-Baseline assesments included any scheduled and unscheduled post-baseline assessment
| Participants | Part 1 (Dose-Finding Period) | Part 2 (Randomized Period) -Placebo | Part 2 (Randomized Period) - Eltrombopag | Part 2/ 3 (Eltrombopag Open-Label Period) |
|---|---|---|---|---|
| Creatinine, high, n=15, 21, 44, 65 | 1 | 3 | 6 | 13 |
| Creatinine, low, n=15, 21, 44, 65 | 5 | 4 | 4 | 12 |
| Creatinine Clearance Derived, high, n=15, 21,44,65 | 11 | 17 | 28 | 46 |
| Creatinine Clearance Derived, low, n=15, 21,44,65 | 0 | 2 | 3 | 4 |
| Protein/Creatinine, high, n=12, 19, 38, 58 | 1 | 2 | 4 | 18 |
| Protein/Creatinine, low, n=12, 19, 38, 58 | 1 | 0 | 0 | 0 |
| Urea, high, n=15, 21, 44, 65 | 1 | 2 | 2 | 5 |
| Urea, low, n=15, 21, 44, 65 | 5 | 1 | 9 | 11 |
Urine microscopy included Red Blood Cell (RBC) casts, white blood cell (WBC) casts, and epithelial renal tubular cell casts. Urine microscopy data was reviewed by the Medical Monitor in order to classify the results as positive or negative. The number of participants with a positive result at any time post Baseline were reported. A positive result indicated if the result was positive for at least one of RBC casts, WBC casts, or epithelial renal tubular cell casts.
| Participants | Part 1 (Dose-Finding Period) Cohort 1 | Part 1 (Dose-Finding Period) Cohort 2 | Part 1 (Dose-Finding Period) Cohort 3 |
|---|---|---|---|
| Epithelial Renal Cell Casts | 0 | 0 | 2 |
| RBC Casts | 0 | 0 | 0 |
| WBC Casts | 0 | 0 | 0 |
Urine microscopy included Red Blood Cell (RBC) casts, white blood cell (WBC) casts, and epithelial renal tubular cell casts. Urine microscopy data was reviewed by the Medical Monitor in order to classify the results as positive or negative. The nmber of participants with positive finding at Baseline and at anytime post-Baseline (Post-BL) were reported. Baseline was defined as the value obtained at the first visit before treatment (Pre-trt). A positive result indicated if the result was positive for at least one of RBC casts, WBC casts, or epithelial renal tubular cell casts.
| Participants | Part 2 (Randomized Period) Cohort 1-Placebo | Part 2 (Randomized Period) Cohort 1- Eltrombopag | Part 2 (Randomized Period) Cohort 2-Placebo | Part 2 (Randomized Period) Cohort 2-Eltrombopag | Part 2 (Randomized Period) Cohort 3-Placebo | Part 2 (Randomized Period) Cohort 3- Eltrombopag |
|---|---|---|---|---|---|---|
| Pre-trt Epithelial Renal Tubular Cell Casts | 0 | 2 | 0 | 0 | 0 | 0 |
| Pre-trt RBC Casts | 0 | 1 | 0 | 0 | 0 | 0 |
| Pre-trt WBC Casts | 0 | 0 | 0 | 0 | 0 | 0 |
| Post-BL Epithelial Renal Tubular Cell Casts | 1 | 3 | 0 | 0 | 1 | 0 |
| Post-BL RBC Casts | 0 | 0 | 0 | 0 | 0 | 0 |
| Post-BL WBC Casts | 0 | 0 | 0 | 0 | 0 | 1 |
Urine microscopy included Red Blood Cell (RBC) casts, white blood cell (WBC) casts, and epithelial renal tubular cell casts. Urine microscopy data was reviewed by the Medical Monitor in order to classify the results as positive or negative. The number of participants with positive finding at Baseline and at anytime post-Baseline (Post-BL) were reported. Baseline was defined as the value obtained at the first visit before treatment (Pre-trt). A positive result indicated if the result was positive for at least one of RBC casts, WBC casts, or epithelial renal tubular cell casts. Participants randomized to receive eltrombopag for 7 weeks in Part 2 continued receiving eltrombopag for an additional 17 weeks in Part 2/3 (for a total of 24 weeks of treatment) up to Study Week 24. Participants randomized to receive placebo for 7 weeks in Part 2, received 24 weeks of eltrombopag in Part 2/3 (for a total of 24 weeks of treatment) up to Study Week 31.
| Participants | Part 2/3 (Eltrombopag Open-Label Period) Cohort 1 | Part 2/3 (Eltrombopag Open-Label Period) Cohort 2 | Part 2/3 (Eltrombopag Open- Label Period) Cohort 3 |
|---|---|---|---|
| Pre-trt Epithelial Renal Tubular Cell Casts | 3 | 0 | 1 |
| Pre-trt RBC Casts | 1 | 0 | 0 |
| Pre-trt WBC Casts | 0 | 0 | 0 |
| Post-BL Epithelial Renal Tubular Cell Casts | 3 | 2 | 1 |
| Post-BL RBC Casts | 0 | 0 | 1 |
| Post-BL WBC Casts | 1 | 0 | 1 |
Vital sign assessments included systolic blood pressure (SBP) and diastolic blood pressure (DBP) measurements that were measured before any blood draw at the following scheduled time points: Screening, Day 1, each week from Week 1 to Week 24, at each Follow-up week (Week 1-4) and the maximum post- Baseline (BL) visit. BL is defined as the value obtained on Day 1of treatment. The maximum post-BL visit (MPB) included any scheduled and unscheduled post-BL assessment. Reference ranges (RR) for SBP (mmHg) (Lower limit of normal, normal, Upper limit of normal) for Cohort 1: \<85, 85-115, \>115; for Cohort 2: \<85, 85-120,\>120; and Cohort 3: \<95, 95-135, \>135. RR for DBP (mmHg) for Cohort 1: \<45, 45-70,\>70; for Cohort 2: \<50, 50-75, \>75; and Cohort 3: \<55, 55-85, \>85.
| Participants | Part 1 Eltrombopag Dose-Finding Period | Part 2 Randomized Period - Placebo | Part 2 Randomized Period - Eltrombopag | Part 2/ 3 (Eltrombopag Open-Label Period) |
|---|---|---|---|---|
| Screening, DBP, high, n=15 ,20 ,41 ,40 | 1 | 4 | 3 | 3 |
| Screening, DBP, low, n=15, 20, 41, 40 | 0 | 2 | 6 | 5 |
| Day 1, DBP, high, n=14, 18, 38, 59 | 2 | 4 | 3 | 7 |
| Day 1, DBP, low, n=14, 18, 38, 59 | 1 | 1 | 3 | 4 |
| Week 1, DBP, high, n=14, 19, 42, 63 | 1 | 3 | 4 | 5 |
| Week 1, DBP, low, n=14, 19, 42, 63 | 1 | 1 | 4 | 5 |
| Week 2, DBP, high, n=15, 20, 42, 61 | 3 | 2 | 2 | 3 |
| Week 2, DBP, low, n=15, 20, 42, 61 | 2 | 3 | 4 | 5 |
| Week 3, DBP, high,n=15, 21, 41, 60 | 1 | 3 | 3 | 6 |
| Week 3, DBP, low,n=15, 21, 41, 60 | 2 | 3 | 5 | 5 |
| Week 4, DBP,high, n=15, 21, 42, 62 | 0 | 3 | 3 | 6 |
| Week 4, DBP,low, n=15, 21, 42, 62 | 4 | 4 | 3 | 5 |
| Week 5, DBP, high, n=15, 19, 40, 59 | 1 | 2 | 4 | 8 |
| Week 5, DBP, low, n=15, 19, 40, 59 | 1 | 1 | 5 | 5 |
| Week 6, DBP, high, n=14, 21, 42, 58 | 1 | 2 | 3 | 5 |
| Week 6, DBP, low, n=14, 21, 42, 58 | 0 | 0 | 3 | 4 |
| Week 7, DBP, high, n=15, 21, 42, 58 | 1 | 4 | 6 | 7 |
| Week 7, DBP, low, n=15, 21, 42, 58 | 0 | 1 | 2 | 4 |
| Week 8, DBP,high,n=15, 0, 0, 49 | 0 | NA | NA | 4 |
| Week 8, DBP,low,n=15, 0, 0, 49 | 1 | NA | NA | 6 |
| Week 9, DBP, high, n=15, 0, 0, 45 | 2 | NA | NA | 4 |
| Week 9, DBP, low, n=15, 0, 0, 45 | 1 | NA | NA | 6 |
| Week 10, DBP, high, n=15, 0, 0, 40 | 0 | NA | NA | 6 |
| Week 10, DBP, low, n=15, 0, 0, 40 | 0 | NA | NA | 3 |
| Week 11, DBP, high, n=13, 0, 0, 41 | 0 | NA | NA | 4 |
| Week 11, DBP, low, n=13, 0, 0, 41 | 2 | NA | NA | 3 |
| Week 12, DBP, high, n=13, 0, 0, 42 | 0 | NA | NA | 5 |
| Week 12, DBP, low, n=13, 0, 0, 42 | 3 | NA | NA | 3 |
| Week 13, DBP, high, n=12, 0, 0, 32 | 0 | NA | NA | 0 |
| Week 13, DBP, low, n=12, 0, 0, 32 | 0 | NA | NA | 5 |
| Week 14, DBP, high, n=9, 0, 0, 32 | 0 | NA | NA | 3 |
| Week 14, DBP, low, n=9, 0, 0, 32 | 1 | NA | NA | 3 |
| Week 15, DBP, high, n=11, 0, 0, 31 | 1 | NA | NA | 3 |
| Week 15, DBP, low, n=11, 0, 0, 31 | 2 | NA | NA | 0 |
| Week 16, DBP,high,n=12, 0, 0, 39 | 0 | NA | NA | 2 |
| Week 16, DBP,low,n=12, 0, 0, 39 | 0 | NA | NA | 3 |
| Week 17, DBP,high,n=5, 0, 0, 29 | 0 | NA | NA | 2 |
| Week 17, DBP,low,n=5, 0, 0, 29 | 1 | NA | NA | 1 |
| Week 18, DBP,high,n=9, 0, 0, 32 | 0 | NA | NA | 3 |
| Week 18, DBP,low,n=9, 0, 0, 32 | 1 | NA | NA | 1 |
| Week 19, DBP,high,n=5, 0, 0, 34 | 0 | NA | NA | 1 |
| Week 19, DBP,low,n=5, 0, 0, 34 | 0 | NA | NA | 2 |
| Week 20, DBP,high,n=13, 0, 0, 33 | 0 | NA | NA | 0 |
| Week 20, DBP,low,n=13, 0, 0, 33 | 0 | NA | NA | 1 |
| Week 21, DBP,high,n=10, 0, 0, 17 | 1 | NA | NA | 1 |
| Week 21, DBP,low,n=10, 0, 0, 17 | 1 | NA | NA | 1 |
| Week 22, DBP,high,n=11, 0, 0, 23 | 1 | NA | NA | 1 |
| Week 22, DBP,low,n=11, 0, 0, 23 | 1 | NA | NA | 0 |
| Week 23, DBP,high,n=11, 0, 0, 21 | 0 | NA | NA | 1 |
| Week 23, DBP,low,n=11, 0, 0, 21 | 2 | NA | NA | 2 |
| Week 24 DBP,high,n=15, 0, 0, 58 | 0 | NA | NA | 5 |
| Week 24, DBP,low,n=15, 0, 0, 58 | 3 | NA | NA | 3 |
| FU Week 1, DBP,high,n=5, 0, 0, 13 | 1 | NA | NA | 2 |
| FU Week 1, DBP,low,n=5, 0, 0, 13 | 1 | NA | NA | 1 |
| FU Week 2, DBP,high,n=5, 0, 0, 21 | 0 | NA | NA | 2 |
| FU Week 2, DBP,low,n=5, 0, 0, 21 | 0 | NA | NA | 1 |
| FU Week 3, DBP,high,n=5, 0, 0, 14 | 0 | NA | NA | 2 |
| FU Week 3, DBP,low,n=5, 0, 0, 14 | 0 | NA | NA | 0 |
| FU Week 4, DBP,high,n=3, 0, 0, 31 | 0 | NA | NA | 7 |
| FU Week 4, DBP,low,n=3, 0, 0, 31 | 1 | NA | NA | 5 |
| Screening, SBP, high, n=15, 20, 41, 40 | 4 | 4 | 10 | 10 |
| Screening, SBP, low, n=15, 20, 41, 40 | 3 | 0 | 3 | 2 |
| Day 1, SBP,high,n=14, 18, 38, 59 | 4 | 5 | 9 | 14 |
| Day 1, SBP,low,n=14, 18, 38, 59 | 0 | 1 | 4 | 4 |
| Week 1, SBP,high,n=14, 19, 42, 63 | 3 | 6 | 14 | 18 |
| Week 1, SBP,low,n=14, 19, 42, 63 | 2 | 0 | 4 | 8 |
| Week 2, SBP,high,n=15, 20, 43, 62 | 4 | 7 | 7 | 15 |
| Week 2, SBP,low,n=15, 20, 43, 62 | 1 | 2 | 5 | 6 |
| Week 3, SBP,high,n=15, 21, 41, 60 | 3 | 4 | 12 | 17 |
| Week 3, SBP,low,n=15, 21, 41, 60 | 1 | 2 | 2 | 3 |
| Week 4, SBP,high,n=15, 21, 42, 62 | 4 | 6 | 10 | 16 |
| Week 4, SBP,low,n=15, 21, 42, 62 | 4 | 1 | 3 | 2 |
| Week 5, SBP,high,n=15, 19, 40, 59 | 5 | 5 | 13 | 17 |
| Week 5, SBP, low, n=15, 19, 40, 59 | 2 | 1 | 3 | 3 |
| Week 6, SBP,high,n=14, 21, 42, 58 | 4 | 8 | 11 | 16 |
| Week 6, SBP,low,n=14, 21, 42, 58 | 2 | 1 | 3 | 5 |
| Week 7, SBP,high,n=15, 21, 42, 58 | 5 | 5 | 9 | 13 |
| Week 7, SBP,low,n=15, 21, 42, 58 | 1 | 0 | 2 | 5 |
| Week 8, SBP,high,n=15, 0, 0, 49 | 3 | NA | NA | 16 |
| Week 8, SBP,low,n=15, 0, 0, 49 | 4 | NA | NA | 4 |
| Week 9, SBP,high,n=15, 0, 0, 45 | 4 | NA | NA | 15 |
| Week 9, SBP,low,n=15, 0, 0, 45 | 3 | NA | NA | 2 |
| Week 10, SBP,high,n=15, 0, 0, 40 | 2 | NA | NA | 10 |
| Week 10, SBP,low,n=15, 0, 0, 40 | 2 | NA | NA | 3 |
| Week 11, SBP,high,n=13, 0, 0, 41 | 4 | NA | NA | 9 |
| Week 11, SBP,low,n=13, 0, 0, 41 | 2 | NA | NA | 2 |
| Week 12, SBP,high,n=13, 0, 0, 42 | 3 | NA | NA | 10 |
| Week 12, SBP,low,n=13, 0, 0, 42 | 3 | NA | NA | 3 |
| Week 13, SBP,high,n=12, 0, 0, 32 | 3 | NA | NA | 8 |
| Week 13, SBP,low,n=12, 0, 0, 32 | 2 | NA | NA | 3 |
| Week 14, SBP,high,n=9, 0, 0, 32 | 4 | NA | NA | 10 |
| Week 14, SBP,low,n=9, 0, 0, 32 | 0 | NA | NA | 3 |
| Week 15, SBP,high,n=11, 0, 0, 31 | 3 | NA | NA | 9 |
| Week 15, SBP,low,n=11, 0, 0, 31 | 2 | NA | NA | 1 |
| Week 16 SBP,high,n=12, 0, 0, 39 | 5 | NA | NA | 14 |
| Week 16, SBP,low,n=12, 0, 0, 39 | 1 | NA | NA | 1 |
| Week 17, SBP,high,n=5, 0, 0, 29 | 1 | NA | NA | 9 |
| Week 17, SBP,low,n=5, 0, 0, 29 | 1 | NA | NA | 0 |
| Week 18, SBP,high,n=9, 0, 0, 32 | 2 | NA | NA | 10 |
| Week 18, SBP,low,n=9, 0, 0, 32 | 0 | NA | NA | 1 |
| Week 19, SBP,high,n=5, 0, 0, 34 | 2 | NA | NA | 9 |
| Week 19, SBP,low,n=5, 0, 0, 34 | 0 | NA | NA | 2 |
| Week 20, SBP,high,n=13, 0, 0, 33 | 6 | NA | NA | 10 |
| Week 20, SBP,low,n=13, 0, 0, 33 | 2 | NA | NA | 1 |
| Week 21, SBP,high,n=10, 0, 0, 17 | 2 | NA | NA | 0 |
| Week 21, SBP,low,n=10, 0, 0, 17 | 3 | NA | NA | 0 |
| Week 22, SBP,high,n=11, 0, 0, 23 | 2 | NA | NA | 8 |
| Week 22, SBP,low,n=11, 0, 0, 23 | 3 | NA | NA | 0 |
| Week 23, SBP,high,n=11, 0, 0, 21 | 2 | NA | NA | 6 |
| Week 23, SBP,low,n=11, 0, 0, 21 | 2 | NA | NA | 1 |
| Week 24, SBP,high,n=15, 0, 0, 58 | 4 | NA | NA | 19 |
| Week 24, SBP, low, n=15, 0, 0, 58 | 2 | NA | NA | 2 |
| FU Week 1, SBP, high,n=5, 0, 0, 13 | 0 | NA | NA | 4 |
| FU Week 1, SBP, low,n=5, 0, 0, 13 | 2 | NA | NA | 0 |
| FU Week 2, SBP, high,n=5, 0, 0, 21 | 2 | NA | NA | 3 |
| FU Week 2, SBP, low,n=5, 0, 0, 21 | 0 | NA | NA | 3 |
| FU Week 3, SBP, high,n=5, 0, 0, 14 | 1 | NA | NA | 4 |
| FU Week 3, SBP, low,n=5, 0, 0, 14 | 0 | NA | NA | 0 |
| FU Week 4, SBP, high,n=3, 0, 0, 31 | 1 | NA | NA | 10 |
| FU Week 4, SBP,low,n=3, 0, 0, 31 | 1 | NA | NA | 3 |
Respiratory rate was measured at the following scheduled time points: Screening, Day 1, each week from Week 1 to Week 24, and at each Follow-up Weeks 1-4. Baseline is defined as the value obtained on Day 1 of treatment. The maximum post-Baseline value included any scheduled and unscheduled post-Baseline assessment.
| Breaths per min | Part 1 (Dose-Finding Period) Cohort 1 | Part 1 (Dose-Finding Period) Cohort 2 | Part 1 (Dose-Finding Period) Cohort 3 |
|---|---|---|---|
| BL, n=4, 5, 4 | 20.0 ± 0.00 | 21.4 ± 4.10 | 25.5 ± 4.43 |
| Week 1, n=4,5,4 | 21.5 ± 4.43 | 22.0 ± 6.00 | 26.5 ± 6.40 |
| Week 2, n=5,5,4 | 20.6 ± 3.44 | 19.4 ± 4.98 | 24.0 ± 5.42 |
| Week 3, n=5,5,5 | 22.0 ± 5.66 | 17.0 ± 5.10 | 23.6 ± 6.07 |
| Week 4, n=5,5,5 | 18.8 ± 1.79 | 17.2 ± 4.82 | 25.4 ± 5.98 |
| Week 5, n=5,5,4 | 20.4 ± 2.19 | 20.2 ± 6.87 | 24.3 ± 5.56 |
| Week 6, n=5,5,4 | 18.4 ± 2.61 | 20.2 ± 5.02 | 24.5 ± 2.52 |
| Week 7, n=5,5,5 | 19.2 ± 1.10 | 23.4 ± 9.15 | 24.4 ± 6.69 |
| Week 8, n=5,5,5 | 19.8 ± 3.03 | 20.4 ± 3.05 | 23.8 ± 4.82 |
| Week 9, n=5,4,5 | 19.2 ± 2.28 | 22.5 ± 3.79 | 22.0 ± 2.00 |
| Week 10, n=5,5,5 | 19.6 ± 2.61 | 18.0 ± 4.00 | 22.4 ± 1.67 |
| Week 11, n=5,3,4 | 19.6 ± 1.67 | 20.3 ± 3.21 | 25.0 ± 5.03 |
| Week 12, n=4,3,4 | 19.5 ± 1.00 | 20.0 ± 0.00 | 27.6 ± 11.52 |
| Week 13, n=4,4,4 | 19.5 ± 1.00 | 21.0 ± 2.16 | 23.0 ± 3.46 |
| Week 14, n=3,3,3 | 18.7 ± 1.15 | 22.7 ± 1.15 | 27.3 ± 7.57 |
| Week 15, n=3,3,3 | 18.0 ± 2.00 | 21.3 ± 1.15 | 24.0 ± 2.00 |
| Week 16, n=5,3,4 | 18.8 ± 3.35 | 20.0 ± 4.00 | 30.8 ± 16.88 |
| Week 17, n=2,0,3 | 18.0 ± 0.00 | NA ± NA | 24.0 ± 4.00 |
| Week 18, n=3,3,4 | 19.3 ± 1.15 | 21.3 ± 3.06 | 29.0 ± 13.22 |
| Week 19, n=3,0,2 | 19.3 ± 1.15 | NA ± NA | 28.0 ± 11.31 |
| Week 20, n=5,4,4 | 19.6 ± 1.67 | 21.5 ± 3.00 | 23.5 ± 3.42 |
| Week 21, n=3,2,5 | 19.3 ± 1.15 | 19.00 ± 1.41 | 23.6 ± 3.51 |
| Week 22, n=3,4,3 | 19.3 ± 2.31 | 21.0 ± 2.00 | 27.3 ± 7.57 |
| Week 23, n=4,2,4 | 20.0 ± 1.63 | 20.0 ± 0.00 | 21.5 ± 1.91 |
| Week 24, n=5,5,4 | 19.6 ± 0.89 | 23.0 ± 3.16 | 24.8 ± 7.09 |
| FU Week 1, n=1,1,3 | 20.0 ± NA | 20.0 ± NA | 22.0 ± 2.00 |
| FU Week 2, n=3,2,0 | 19.3 ± 1.15 | 26.5 ± 9.19 | NA ± NA |
| FU Week 3, n=2,1,2 | 21.0 ± 4.24 | 28.0 ± NA | 24.5 ± 4.95 |
| FU Week 4, n=1,0,1 | 18.0 ± NA | NA ± NA | 24.0 ± NA |
| MPB, n=5, 5, 5 | 24.4 ± 4.56 | 29.8 ± 6.02 | 32.2 ± 13.90 |
Respiratory rate was measured at the following scheduled time points: Screening, Day 1, each week from Week 1 to Week 24, and at each Follow-up Weeks 1-4. Baseline is defined as the value obtained on Day 1 of treatment. The maximum post-Baseline value included any scheduled and unscheduled post-Baseline assessment.
| Breaths per min | Part 2 (Randomized Period) Cohort 1-Placebo | Part 2 (Randomized Period) Cohort 1- Eltrombopag | Part 2 (Randomized Period) Cohort 2-Placebo | Part 2 (Randomized Period) Cohort 2-Eltrombopag | Part 2 (Randomized Period) Cohort 3-Placebo | Part 2 (Randomized Period) Cohort 3- Eltrombopag |
|---|---|---|---|---|---|---|
| BL, n= 5, 14, 9, 12, 3, 10 | 19.6 ± 1.67 | 18.4 ± 2.38 | 19.4 ± 3.13 | 21.5 ± 10.03 | 18.7 ± 1.15 | 21.4 ± 2.12 |
| Week 1, n=7, 16 ,9, 17, 2, 10 | 19.0 ± 1.00 | 18.8 ± 1.76 | 19.9 ± 2.26 | 20.7 ± 4.48 | 19.0 ± 1.41 | 28.2 ± 9.54 |
| Week 2, n=6, 15, 9, 16, 4, 10 | 19.3 ± 2.73 | 18.9 ± 2.70 | 19.8 ± 2.33 | 23.0 ± 8.01 | 21.5 ± 5.00 | 27.1 ± 11.70 |
| Week 3, n=8, 16, 9, 16, 4, 9 | 18.8 ± 1.83 | 18.9 ± 1.93 | 20.1 ± 2.76 | 22.3 ± 4.78 | 21.0 ± 2.58 | 25.8 ± 7.17 |
| Week 4, n=7, 16, 8, 14, 4, 10 | 19.4 ± 2.51 | 18.6 ± 2.80 | 19.8 ± 2.49 | 21.4 ± 4.29 | 21.5 ± 1.00 | 25.4 ± 7.18 |
| Week 5, n=8, 16, 8, 15, 3, 8 | 19.3 ± 1.04 | 18.5 ± 2.10 | 20.5 ± 2.98 | 19.7 ± 2.74 | 20.0 ± 2.00 | 29.0 ± 14.77 |
| Week 6, n=8, 16, 9, 15, 4, 9 | 20.3 ± 2.25 | 19.4 ± 2.16 | 20.6 ± 2.19 | 20.6 ± 4.12 | 21.0 ± 1.15 | 24.4 ± 6.69 |
| Week 7, n=7, 16, 9, 17, 4, 8 | 20.9 ± 2.27 | 18.4 ± 1.50 | 20.9 ± 3.33 | 20.7 ± 7.87 | 18.5 ± 1.91 | 23.5 ± 6.12 |
| MPB, n=8, 16, 9, 17, 4, 11 | 21.5 ± 2.33 | 21.3 ± 21.8 | 22.7 ± 2.45 | 26.6 ± 7.87 | 23.5 ± 3.42 | 30.0 ± 13.39 |
Respiratory rate was measured at the following scheduled time points: Screening, Day 1, each week from Week 1 to Week 24, and at each Follow-up Weeks 1-4. Baseline is defined as the value obtained on Day 1 of treatment. The maximum post-Baseline visit included any scheduled and unscheduled post-Baseline assessment. Participants randomized to receive eltrombopag for 7 weeks in Part 2 continued receiving eltrombopag for an additional 17 weeks in Part 2/3 (for a total of 24 weeks of treatment) up to Study Week 24. Participants randomized to receive placebo for 7 weeks in Part 2, received 24 weeks of eltrombopag in Part 2/3 (for a total of 24 weeks of treatment) up to Study Week 31.
| Breaths per minute | Part 2/3 (Eltrombopag Period) Cohort 1 | Part 2/3 (Eltrombopag Period) Cohort 2 | Part 2/3 (Eltrombopag Period) Cohort 3 |
|---|---|---|---|
| Screening, n=16, 14, 10 | 18.5 ± 1.75 | 21.2 ± 6.57 | 21.5 ± 2.56 |
| Day 1 , n=21, 21, 15 | 19.2 ± 2.57 | 2.12 ± 7.74 | 21.7 ± 4.76 |
| Week 1, n=24, 25, 14 | 19.1 ± 1.74 | 20.4 ± 3.93 | 25.1 ± 7.63 |
| Week 2, n=22, 24, 13 | 19.4 ± 2.56 | 21.8 ± 6.85 | 25.2 ± 10.83 |
| Week 3, n=24, 23, 12 | 18.8 ± 1.73 | 21.2 ± 4.40 | 24.0 ± 6.09 |
| Week 4, n=23, 23, 13 | 19.0 ± 2.59 | 20.9 ± 3.82 | 24.3 ± 6.37 |
| Week 5, n=23, 23, 11 | 18.9 ± 2.13 | 19.8 ± 3.19 | 26.9 ± 12.91 |
| Week 6, n=23, 22, 11 | 19.3 ± 2.30 | 20.6 ± 4.11 | 23.3 ± 4.92 |
| Week 7, n=22, 25, 11 | 18.8 ± 1.99 | 20.1 ± 4.46 | 22.4 ± 4.60 |
| Week 8, n=19, 19, 10 | 19.2 ± 2.32 | 23.4 ± 6.23 | 22.0 ± 1.79 |
| Week 9, n=17, 16, 12 | 19.5 ± 2.96 | 22.0 ± 3.95 | 22.5 ± 4.48 |
| Week 10, n=16, 13, 11 | 18.7 ± 2.27 | 22.8 ± 3.83 | 23.3 ± 6.83 |
| Week 11, n=15, 13, 12 | 18.9 ± 1.28 | 22.8 ± 3.11 | 22.2 ± 5.29 |
| Week 12, n=17, 16, 9 | 18.6 ± 1.90 | 22.2 ± 3.76 | 23.6 ± 4.98 |
| Week 13, n=11, 13, 8 | 19.3 ± 1.56 | 23.4 ± 7.68 | 21.0 ± 2.62 |
| Week 14, n=13, 11, 7 | 18.7 ± 2.98 | 19.9 ± 5.49 | 23.4 ± 4.86 |
| Week 15, n=12, 13, 5 | 18.7 ± 1.76 | 21.1 ± 2.53 | 24.4 ± 8.76 |
| Week 16, n=16, 14, 8 | 18.6 ± 1.26 | 22.9 ± 7.97 | 24.3 ± 6.88 |
| Week 17, n=13, 10, 5 | 19.0 ± 2.08 | 22.4 ± 6.45 | 25.2 ± 9.65 |
| Week 18, n=16, 12, 4 | 19.1 ± 3.79 | 22.0 ± 4.53 | 29.0 ± 10.52 |
| Week 19, n=14, 13, 6 | 18.1 ± 1.49 | 24.5 ± 19.33 | 24.0 ± 6.45 |
| Week 20, n=13, 13, 7 | 17.4 ± 1.94 | 20.9 ± 3.52 | 33.00 ± 16.77 |
| Week 21, n=4, 10, 3 | 18.8 ± 3.40 | 20.2 ± 3.55 | 28.0 ± 10.58 |
| Week 22, n=11, 7, 5 | 19.7 ± 2.94 | 19.1 ± 2.79 | 26.0 ± 4.90 |
| Week 23, n=8, 7, 6 | 20.4 ± 2.72 | 21.1 ± 3.24 | 23.7 ± 5.13 |
| Week 24, n=22, 23, 11 | 19.1 ± 2.03 | 20.2 ± 3.11 | 23.8 ± 5.47 |
| FU Week 1, n=6, 6, 3 | 18.8 ± 1.60 | 20.0 ± 3.41 | 26.0 ± 10.39 |
| FU Week 2, n=6, 5, 7 | 18.7 ± 1.63 | 20.8 ± 4.15 | 22.2 ± 4.02 |
| FU Week 3, n=6, 4, 4 | 19.0 ± 1.67 | 23.0 ± 4.16 | 24.8 ± 5.50 |
| FU Week 4, n=10, 12, 7 | 19.4 ± 0.97 | 20.8 ± 1.86 | 21.0 ± 3.74 |
| MPB, n=24, 26, 15 | 23.0 ± 2.78 | 27.7 ± 13.00 | 27.7 ± 11.54 |
Pulse rate was measured at the following scheduled time points: Screening, Day 1, each week from Week 1 to Week 24, and at each Follow-up Weeks 1-4. Baseline is defined as the value obtained on Day 1 of treatment. The maximum post-Baseline (MPB) visit included any scheduled and unscheduled post-Baseline assessment..
| Beats per minute | Part 1 (Dose-Finding Period) Cohort 1 | Part 1 (Dose-Finding Period) Cohort 2 | Part 1 (Dose-Finding Period) Cohort 3 |
|---|---|---|---|
| Screening, n=5, 5, 5 | 85.2 ± 15.71 | 88.4 ± 8.50 | 102.0 ± 7.97 |
| Day 1, n=4, 5, 5, | 84.3 ± 11.32 | 88.2 ± 12.89 | 102.4 ± 13.22 |
| Week 1, n= 4, 5, 5 | 85.3 ± 4.79 | 90.8 ± 11.19 | 103.8 ± 8.47 |
| Week 2, n=5, 5, 5 | 80.4 ± 12.97 | 84.4 ± 16.77 | 96.8 ± 10.66 |
| Week 3, n=5, 5, 5 | 92.8 ± 31.16 | 91.4 ± 11.04 | 106.2 ± 11.10 |
| Week 4, n=5, 5, 5 | 86.4 ± 10.92 | 84.0 ± 7.62 | 98.6 ± 14.29 |
| Week 5, n=5, 5, 5 | 84.6 ± 9.48 | 88.4 ± 9.58 | 107.8 ± 9.58 |
| Week 6, n=5, 5, 4 | 76.4 ± 10.50 | 89.8 ± 13.79 | 103.0 ± 8.29 |
| Week 7, n=5, 5, 5 | 82.0 ± 9.46 | 96.2 ± 17.84 | 103.2 ± 8.93 |
| Week 8, n=5, 5, 5 | 83.0 ± 5.20 | 89.4 ± 15.04 | 111.8 ± 10.62 |
| Week 9, n=5, 5, 5 | 80.4 ± 13.35 | 79.2 ± 11.34 | 101.6 ± 5.59 |
| Week 10, n=5, 5, 5 | 80.6 ± 14.93 | 84.4 ± 10.31 | 105.4 ± 9.29 |
| Week 11, n=5, 3, 5 | 86.6 ± 11.04 | 97.7 ± 16.50 | 106.6 ± 11.19 |
| Week 12, n=4, 4, 5 | 80.5 ± 12.07 | 92.0 ± 12.83 | 101.4 ± 16.62 |
| Week 13, n=4, 4, 4 | 90.8 ± 15.52 | 86.5 ± 7.05 | 103.8 ± 3.50 |
| Week 14, n=3, 3, 3 | 81.0 ± 9.85 | 87.0 ± 8.66 | 101.0 ± 11.00 |
| Week 15, n=3, 4, 4 | 77.3 ± 6.66 | 86.8 ± 11.87 | 102.5 ± 3.87 |
| Week 16, n=5, 3, 4 | 86.4 ± 18.60 | 103.0 ± 5.57 | 93.0 ± 18.96 |
| Week 17, n=2, 0, 3 | 67.5 ± 20.51 | NA ± NA | 97.7 ± 12.01 |
| Week 18, n=3, 3, 4 | 88.0 ± 10.44 | 86.7 ± 17.01 | 102.8 ± 16.88 |
| Week 19, n=3, 0, 2 | 88.0 ± 20.81 | NA ± NA | 94.0 ± 8.49 |
| Week 20, n=5, 4, 4 | 79.8 ± 13.03 | 96.8 ± 12.58 | 111.8 ± 14.97 |
| Week 21, n=3, 2, 5 | 79.0 ± 6.93 | 75.5 ± 3.54 | 101.0 ± 18.63 |
| Week 22, n=3, 4, 4 | 70.3 ± 14.36 | 86.5 ± 9.04 | 100.0 ± 18.63 |
| Week 23, n=4, 2, 5 | 71.5 ± 13.03 | 82.5 ± 3.54 | 100.0 ± 13.14 |
| Week 24, n=5, 5, 5 | 79.6 ± 7.86 | 85.8 ± 6.91 | 96.0 ± 4.74 |
| FU Week 1, n=1, 1, 3 | 81.0 ± NA | 125.0 ± NA | 107.7 ± 10.79 |
| FU Week 2, n=3, 2, 0 | 77.7 ± 8.74 | 84.5 ± 28.99 | NA ± NA |
| FU Week 3, n=2, 1, 2 | 87.0 ± 2.83 | 78.0 ± NA | 98.0 ± 8.49 |
| FU Week 4, n=1, 0, 2 | 89.0 ± NA | NA ± NA | 99.0 ± 26.87 |
| MBP, n=5, 5, 5 | 108.8 ± 24.01 | 109.8 ± 14.17 | 119.6 ± 5.73 |
Pulse rate was measured at the following scheduled time points: Screening, Day 1, each week from Week 1 to Week 24, and at each Follow-up Weeks 1-4. Baseline is defined as the value obtained on Day 1 of treatment. The maximum post-Baseline visit included any scheduled and unscheduled post-Baseline assessment.
| Beats per minute | Part 2 (Randomized Period) Cohort 1-Placebo | Part 2 (Randomized Period) Cohort 1- Eltrombopag | Part 2 (Randomized Period) Cohort 2-Placebo | Part 2 (Randomized Period) Cohort 2-Eltrombopag | Part 2 (Randomized Period) Cohort 3-Placebo | Part 2 (Randomized Period) Cohort 3- Eltrombopag |
|---|---|---|---|---|---|---|
| Screening, n=8, 16, 9, 15 | 80.1 ± 10.11 | 82.8 ± 17.28 | 86.9 ± 16.10 | 94.3 ± 17.53 | 91.5 ± 6.56 | 101.5 ± 23.48 |
| Day 1, n=6, 14, 9, 13 | 77.2 ± 12.32 | 81.3 ± 8.70 | 93.0 ± 14.04 | 88.8 ± 12.84 | 98.7 ± 5.69 | 99.6 ± 15.84 |
| Week 1, n=8, 16, 9, 17 | 76.4 ± 8.50 | 80.1 ± 12.04 | 89.9 ± 18.48 | 98.4 ± 19.76 | 98.5 ± 13.44 | 96.4 ± 17.08 |
| Week 2, n=7, 15, 9, 17 | 79.4 ± 8.75 | 81.7 ± 9.79 | 89.0 ± 12.44 | 91.8 ± 16.96 | 95.3 ± 7.09 | 102.5 ± 11.81 |
| Week 3, n=8, 16, 9, 16 | 81.5 ± 12.21 | 84.0 ± 10.93 | 86.6 ± 13.39 | 95.8 ± 13.57 | 97.0 ± 14.67 | 102.6 ± 17.44 |
| Week 4, n=8, 16, 9, 16 | 76.3 ± 6.96 | 82.4 ± 10.39 | 84.4 ± 15.91 | 91.5 ± 14.45 | 93.5 ± 17.00 | 116.1 ± 23.26 |
| Week 5, n=8, 16, 9, 16 | 79.3 ± 9.44 | 82.5 ± 13.87 | 95.3 ± 14.96 | 92.4 ± 15.18 | 89.0 ± 15.52 | 99.8 ± 19.51 |
| Week 6, n=8, 16, 9, 17 | 77.0 ± 9.50 | 83.2 ± 11.01 | 86.8 ± 11.62 | 90.1 ± 17.74 | 84.8 ± 13.15 | 103.0 ± 23.14 |
| Week 7, n=8, 16, 9, 17 | 74.1 ± 6.92 | 82.8 ± 11.68 | 96.7 ± 15.39 | 91.6 ± 17.68 | 101.5 ± 16.60 | 105.3 ± 15.18 |
| MBP, n=8, 16, 9, 17 | 88.3 ± 7.72 | 97.6 ± 7.51 | 106.1 ± 11.92 | 108.6 ± 17.08 | 106.8 ± 12.28 | 117.5 ± 21.68 |
Pulse rate was measured at the following scheduled time points: Screening, Day 1, each week from Week 1 to Week 24, and at each Follow-up Weeks 1-4. Baseline is defined as the value obtained on Day 1 of treatment. The maximum post-Baseline visit included any scheduled and unscheduled post-Baseline assessment. Participants randomized to receive eltrombopag for 7 weeks in Part 2 continued receiving eltrombopag for an additional 17 weeks in Part 2/3 (for a total of 24 weeks of treatment) up to Study Week 24. Participants randomized to receive placebo for 7 weeks in Part 2, received 24 weeks of eltrombopag in Part 2/3 (for a total of 24 weeks of treatment) up to Study Week 31.
| Beats per minute | Part 2/3 (Eltrombopag Period) Cohort 1 | Part 2/3 (Eltrombopag Period) Cohort 2 | Part 2/3 (Eltrombopag Period) Cohort 3 |
|---|---|---|---|
| Screening, n=16, 15, 10 | 82.8 ± 17.28 | 94.3 ± 17.53 | 104.8 ± 21.82 |
| Day 1 , n=22, 22, 15 | 78.7 ± 8.67 | 92.0 ± 14.14 | 100.8 ± 15.71 |
| Week 1, n=24, 26, 14 | 79.9 ± 10.82 | 94.8 ± 17.54 | 97.8 ± 15.67 |
| Week 2, n=23, 26, 13 | 79.9 ± 10.02 | 92.5 ± 16.91 | 99.8 ± 12.64 |
| Week 3, n=24, 24, 12 | 83.3 ± 10.63 | 95.4 ± 12.31 | 99.4 ± 16.56 |
| Week 4, n=24, 25, 13 | 81.9 ± 9.81 | 91.7 ± 13.42 | 110.6 ± 22.55 |
| Week 5, n=24, 24, 11 | 80.8 ± 13.00 | 91.7 ± 14.72 | 97.4 ± 17.92 |
| Week 6, n=23, 24, 11 | 82.2 ± 10.45 | 91.6 ± 16.82 | 102.8 ± 20.31 |
| Week 7, n=22, 25, 11 | 82.1 ± 11.47 | 91.1 ± 16.61 | 101.5 ± 16.91 |
| Week 8, n=19, 20, 10 | 79.9 ± 11.85 | 90.8 ± 16.68 | 94.2 ± 25.71 |
| Week 9, n=17, 16, 12 | 87.4 ± 15.75 | 91.9 ± 17.79 | 100.9 ± 15.19 |
| Week 10, n=16, 13, 11 | 87.9 ± 11.74 | 94.3 ± 17.82 | 97.8 ± 18.77 |
| Week 11, n=15, 14, 12 | 81.5 ± 10.20 | 89.3 ± 16.28 | 99.3 ± 15.39 |
| Week 12, n=17, 16, 9 | 81.1 ± 11.98 | 91.1 ± 16.39 | 105.3 ± 19.58 |
| Week 13, n=11, 13, 8 | 78.1 ± 8.47 | 97.0 ± 21.79 | 99.5 ± 20.57 |
| Week 14, n=13, 12, 7 | 74.5 ± 11.15 | 94.8 ± 18.07 | 95.6 ± 12.09 |
| Week 15, n=12, 14, 5 | 82.5 ± 9.41 | 94.4 ± 18.94 | 98.0 ± 8.72 |
| Week 16, n=17, 14, 8v | 81.3 ± 11.24 | 91.4 ± 15.08 | 99.8 ± 17.16 |
| Week 17, n=13, 11, 5 | 79.7 ± 11.69 | 96.1 ± 20.80 | 102.2 ± 22.61 |
| Week 18, n=16, 12, 4 | 81.1 ± 8.79 | 95.8 ± 23.01 | 99.8 ± 5.56 |
| Week 19, n=14, 14, 6 | 82.1 ± 12.33 | 96.5 ± 20.24 | 104.2 ± 18.88 |
| Week 20, n=13, 13, 7 | 79.0 ± 10.98 | 95.9 ± 17.44 | 91.6 ± 17.18 |
| Week 21, n=4, 10, 3 | 82.3 ± 10.53 | 90.3 ± 10.71 | 99.7 ± 15.28 |
| Week 22, n=11, 6, 5 | 83.2 ± 10.57 | 99.7 ± 5.50 | 98.6 ± 18.20 |
| Week 23, n=8, 7, 6 | 80.4 ± 11.25 | 89.0 ± 22.38 | 96.2 ± 10.68 |
| Week 24, n=23, 23, 11 | 81.2 ± 9.70 | 93.5 ± 12.59 | 95.3 ± 17.75 |
| FU Week 1, n=6, 6, 3 | 86.3 ± 5.85 | 94.2 ± 18.03 | 100.0 ± 20.07 |
| FU Week 2, n=8, 7, 7 | 83.0 ± 8.54 | 87.9 ± 12.77 | 110.0 ± 27.47 |
| FU Week 3, n=6, 5, 4 | 83.7 ± 13.03 | 92.4 ± 11.55 | 92.0 ± 12.19 |
| FU Week 4, n=11, 13, 7 | 81.6 ± 11.89 | 92.3 ± 16.10 | 102.3 ± 18.87 |
| MPB, n=24, 26, 15 | 102.2 ± 9.35 | 110.9 ± 15.03 | 121.2 ± 20.42 |
Urinalysis parameters included: urine protein (UP), urine glucose (UG), urine ketones (UK), urine occult blood (UOB), and pH. The dipstick test gives results in a semi-quantitative manner. UP was categorized as missing (MS), no result (NR), negative (Neg), Trace, 1+, 2+, 3+ and 4+. UG results were categorized as MS, NR, Neg, normal, 5, 15(1+), 30(2+), 60(3+), 110(4+)UK parameters were categorized as as MS, NR, Neg, Trace(5), Small(15), Moderate(40), Large(80), Large(160). UOB parameters were categorized as MS, NR, Neg, 1+, 2+, 3+, Non haemolysed trace, and haemolysed trace. PH results were categorized as MS. NR, normalresult, Neg, and range of pH (from 5-9in increments of 0.5). Data for indicated parameters was reported at Baseline (BL) and Week 24 (W24). The Baseline value was the measurement taken at Day 1.
| Participants | Part 1 Eltrombopag Dose-Finding Period |
|---|---|
| UP, MS, BL, n=3 | 1 |
| UP, NR, BL, n=3 | 0 |
| UP, Neg, BL, n=3 | 0 |
| UP, Trace, BL, n=3 | 2 |
| UP, 1+, BL, n=3 | 0 |
| UP, 2+, BL, n=3 | 0 |
| UP, 3+, BL, n=3 | 0 |
| UP, 4+, BL, n=3 | 0 |
| UG, MS, BL, n=3 | 0 |
| UG, NR, BL, n=3 | 0 |
| UG, Neg, BL, n=3 | 3 |
| UG, normal, BL, n=3 | 0 |
| UG, 5, BL, n=3 | 0 |
| UG, 15(1+), BL, n=3 | 0 |
| UG, 30(2+), BL, n=3 | 0 |
| UG, 60(3+), BL, n=3 | 0 |
| UG, 110(4+), BL, n=3 | 0 |
| UK, MS, BL, n=3 | 0 |
| UK, NR, BL, n=3 | 0 |
| UK, Neg, BL, n=3 | 3 |
| UK, Trace(5), BL, n=3 | 0 |
| UK, Small(15), BL, n=3 | 0 |
| UK, Moderate(40), BL, n=3 | 0 |
| UK, Large(80), BL, n=3 | 0 |
| UK, Large(160), BL, n=3 | 0 |
| UOB, MS, BL,n=3 | 1 |
| UOB, NR, BL,n=3 | 0 |
| UOB, Neg, BL,n=3 | 2 |
| UOB, 1+, BL,n=3 | 0 |
| UOB, 2+, BL,n=3 | 0 |
| UOB, 3+, BL,n=3 | 0 |
| UOB, Non haemolysed trace, BL,n=3 | 0 |
| UOB, haemolysed trace, BL,n=3 | 0 |
| pH, MS, BL, n=3 | 0 |
| pH, NR, BL, n=3 | 0 |
| pH, normal result, BL, n=3 | 0 |
| pH, Neg, BL, n=3 | 0 |
| pH, 5, BL, n=3 | 0 |
| pH, 5.5, BL, n=3 | 0 |
| pH, 6, BL, n=3 | 0 |
| pH, 6.5, BL, n=3 | 1 |
| pH, 7, BL, n=3 | 0 |
| pH, 7.5,BL, n=3 | 1 |
| pH, 8, BL, n=3 | 1 |
| pH, 8.5, BL, n=3 | 0 |
| pH, 9, BL, n=3 | 0 |
| UP, MS, W24, n=4 | 0 |
| UP, NR, W24, n=4 | 0 |
| UP, Neg, W24, n=4 | 3 |
| UP, Trace, W24, n=4 | 1 |
| UP, 1+, W24, n=4 | 0 |
| UP, 2+, W24, n=4 | 0 |
| UP, 3+, W24, n=4 | 0 |
| UP, 4+, W24, n=4 | 0 |
| UG, MS, W24, n=4 | 0 |
| UG, NR, W24, n=4 | 0 |
| UG, Neg, W24, n=4 | 4 |
| UG, normal, W24, n=4 | 0 |
| UG, 5, W24, n=4 | 0 |
| UG, 15(1+), W24, n=4 | 0 |
| UG, 30(2+), W24, n=4 | 0 |
| UG, 60(3+), W24, n=4 | 0 |
| UG, 110(4+), W24, n=4 | 0 |
| UK, MS, W24, n=4 | 0 |
| UK, NR, W24, n=4 | 0 |
| UK, Neg, W24, n=4 | 3 |
| UK, Trace(5), W24, n=4 | 1 |
| UK, Small(15), W24, n=4 | 0 |
| UK, Moderate(40), W24, n=4 | 0 |
| UK, Large(80), W24, n=4 | 0 |
| UK, Large(160), W24, n=4 | 0 |
| UOB, MS, W24, n=4 | 0 |
| UOB, NR, W24, n=4 | 0 |
| UOB, Neg, W24, n=4 | 3 |
| UOB, 1+, W24, n=4 | 0 |
| UOB, 2+, W24, n=4 | 0 |
| UOB, 3+, W24, n=4 | 0 |
| UOB, Non haemolysed trace, W24, n=4 | 0 |
| UOB, haemolysed trace, W24, n=4 | 0 |
| pH, MS, W24, n=4 | 0 |
| pH, NR, W24, n=4 | 0 |
| pH, normal result, W24, n=4 | 0 |
| pH, Neg, W24, n=4 | 0 |
| pH, 5, W24, n=4 | 0 |
| pH, 5.5, W24, n=4 | 0 |
| pH, 6, W24, n=4 | 2 |
| pH, 6.5, W24, n=4 | 2 |
| pH, 7, W24, n=4 | 0 |
| pH, 7.5,W24, n=4 | 0 |
| pH, 8, W24, n=4 | 0 |
| pH, 8.5, W24, n=4 | 0 |
| pH, 9, W24, n=4 | 0 |
Urinalysis parameters included: urine protein (UP), urine glucose (UG), urine ketones (UK), urine occult blood (UOB), and pH. The dipstick test gives results in a semi-quantitative manner. UP was categorized as missing (MS), no result (NR), negative (Neg), Trace, 1+, 2+, 3+ and 4+. UG results were categorized as MS, NR, Neg, normal, 5, 15(1+), 30(2+), 60(3+), 110(4+)UK parameters were categorized as as MS, NR, Neg, Trace(5), Small(15), Moderate(40), Large(80), Large(160). UOB parameters were categorized as MS, NR, Neg, 1+, 2+, 3+, Non haemolysed trace, and haemolysed trace. PH results were categorized as MS. NR, normalresult, Neg, and range of pH (from 5-9in increments of 0.5). Data for indicated parameters was reported at Baseline (BL) and Week 7 (W7). The Baseline value was the measurement taken at Day 1.
| Participants | Part 2 Randomized Period - Placebo | Part 2 Randomized Period - Eltrombopag |
|---|---|---|
| UP, MS, BL, n=10, 9 | 2 | 0 |
| UP, NR, BL, n=10, 9 | 0 | 1 |
| UP, Neg, BL, n=10, 9 | 7 | 8 |
| UP, Trace, BL, n=10, 9 | 1 | 0 |
| UP, 1+, BL, n=10, 9 | 0 | 0 |
| UP, 2+, BL, n=10, 9 | 0 | 0 |
| UP, 3+, BL, n=10, 9 | 0 | 0 |
| UP, 4+, BL, n=10, 9 | 0 | 0 |
| UG, MS, BL, n=10, 9 | 2 | 0 |
| UG, NR, BL, n=10, 9 | 0 | 1 |
| UG, Neg, BL, n=10, 9 | 6 | 8 |
| UG, normal, BL, n=10, 9 | 2 | 0 |
| UG, 5, BL, n=10, 9 | 0 | 0 |
| UG, 15(1+), BL, n=10, 9 | 0 | 0 |
| UG, 30(2+), BL, n=10, 9 | 0 | 0 |
| UG, 60(3+), BL, n=10, 9 | 0 | 0 |
| UG, 110(4+), BL, n=10, 9 | 0 | 0 |
| UK, MS, BL, n=10, 9 | 2 | 0 |
| UK, NR, BL, n=10, 9 | 0 | 1 |
| UK, Neg, BL, n=10, 9 | 8 | 8 |
| UK, Trace(5), BL, n=10, 9 | 0 | 0 |
| UK, Small(15), BL, n=10, 9 | 0 | 0 |
| UK, Moderate(40), BL, n=10, 9 | 0 | 0 |
| UK, Large(80), BL, n=10, 9 | 0 | 0 |
| UK, Large(160), BL, n=10, 9 | 0 | 0 |
| UOB, MS, BL, n=9, 9 | 2 | 1 |
| UOB, NR, BL, n=9, 9 | 0 | 1 |
| UOB, Neg, BL, n=9, 9 | 6 | 4 |
| UOB, 1+, BL,n=9, 9 | 0 | 1 |
| UOB, 2+, BL,n=9, 9 | 1 | 0 |
| UOB, 3+, BL, n=9, 9 | 0 | 0 |
| UOB, Non haemolysed trace, BL,n=9, 9 | 0 | 0 |
| UOB, haemolysed trace, BL, n=9, 9 | 0 | 0 |
| pH, MS, BL, n=10, 9 | 0 | 0 |
| pH, NR, BL, n=10, 9 | 0 | 1 |
| pH, normal result, BL, n=10, 9 | 0 | 0 |
| pH, Neg, BL, n=10, 9 | 0 | 0 |
| pH, 5, BL, n=10, 9 | 1 | 1 |
| pH, 5.5, BL, n=10, 9 | 1 | 1 |
| pH, 6, BL, n=10, 9 | 3 | 4 |
| pH, 6.5, BL, n=10, 9 | 2 | 1 |
| pH, 7, BL, n=10, 9 | 1 | 0 |
| pH, 7.5,BL, n=10, 9 | 1 | 1 |
| pH, 8, BL, n=10, 9 | 1 | 0 |
| pH, 8.5, BL, n=10, 9 | 0 | 0 |
| pH, 9, BL, n=10, 9 | 0 | 0 |
| UP, MS, W7, n=2, 3 | 0 | 0 |
| UP, NR, W7, n=2, 3 | 0 | 0 |
| UP, Neg, W7, n=2, 3 | 2 | 3 |
| UP, Trace, W7, n=2, 3 | 0 | 0 |
| UP, 1+, W7, n=2, 3 | 0 | 0 |
| UP, 2+, W7, n=2, 3 | 0 | 0 |
| UP, 3+, W7, n=2, 3 | 0 | 0 |
| UP, 4+, W7, n=2, 3 | 0 | 0 |
| UG, MS, W7, n=2, 3 | 0 | 0 |
| UG, NR, W7, n=2, 3 | 0 | 0 |
| UG, Neg, W7, n=2, 3 | 2 | 3 |
| UG, normal, W7, n=2, 3 | 0 | 0 |
| UG, 5, W7, n=2, 3 | 0 | 0 |
| UG, 15(1+), W7, n=2, 3 | 0 | 0 |
| UG, 30(2+), W7, n=2, 3 | 0 | 0 |
| UG, 60(3+), W7, n=2, 3 | 0 | 0 |
| UG, 110(4+), W7, n=2, 3 | 0 | 0 |
| UK, MS, W7, n=2, 3 | 0 | 0 |
| UK, NR, W7, n=2, 3 | 0 | 0 |
| UK, Neg, W7, n=2, 3 | 2 | 3 |
| UK, Trace(5), W7, n=2, 3 | 0 | 0 |
| UK, Small(15), W7, n=2, 3 | 0 | 0 |
| UK, Moderate(40), W7, n=2, 3 | 0 | 0 |
| UK, Large(80), W7, n=2, 3 | 0 | 0 |
| UK, Large(160), W7, n=2, 3 | 0 | 0 |
| UOB, MS, W7, n=2, 3 | 1 | 0 |
| UOB, NR, W7, n=2, 3 | 0 | 0 |
| UOB, Neg, W7, n=2, 3 | 1 | 3 |
| UOB, 1+, W7, n=2, 3 | 0 | 0 |
| UOB, 2+, W7, n=2, 3 | 0 | 0 |
| UOB, 3+, W7, n=2, 3 | 0 | 0 |
| UOB, Non haemolysed trace, W7, n=2, 3 | 0 | 0 |
| UOB, haemolysed trace, W7, n=2, 3 | 0 | 0 |
| pH, MS, W7, n=2, 3 | 0 | 0 |
| pH, NR, W7, n=2, 3 | 0 | 0 |
| pH, normal result, W7, n=2, 3 | 0 | 0 |
| pH, Neg, W7, n=2, 3 | 0 | 0 |
| pH, 5, W7, n=2, 3 | 1 | 0 |
| pH, 5.5, W7, n=2, 3 | 0 | 0 |
| pH, 6, W7, n=2, 3 | 0 | 1 |
| pH, 6.5, W7, n=2, 3 | 0 | 1 |
| pH, 7, W7, n=2, 3 | 1 | 1 |
| pH, 7.5, W7, n=2, 3 | 0 | 0 |
| pH, 8, W7, n=2, 3 | 0 | 0 |
| pH, 8.5, W7, n=2, 3 | 0 | 0 |
| pH, 9, W7, n=2, 3 | 0 | 0 |
Urinalysis parameters included: urine protein (UP), urine glucose (UG), urine ketones (UK), urine occult blood (UOB), and pH. The dipstick test gives results in a semi-quantitative manner. UP was categorized as missing (MS), no result (NR), negative (Neg), Trace, 1+, 2+, 3+ and 4+. UG results were categorized as MS, NR, Neg, normal, 5, 15(1+), 30(2+), 60(3+), 110(4+)UK parameters were categorized as as MS, NR, Neg, Trace(5), Small(15), Moderate(40), Large(80), Large(160). UOB parameters were categorized as MS, NR, Neg, 1+, 2+, 3+, Non haemolysed trace, and haemolysed trace. PH results were categorized as MS. NR, normalresult, Neg, and range of pH (from 5-9in increments of 0.5). Data for indicated parameters was reported at Baseline (BL) and Week 24 (W24). The Baseline value was the measurement taken at Day 1.
| Participants | Part 2/ 3 Eltrombopag Open-Label Period |
|---|---|
| UP, MS, BL, n=11 | 0 |
| UP, NR, BL, n=11 | 1 |
| UP, Neg, BL, n=11 | 10 |
| UP, Trace, BL, n=11 | 0 |
| UP, 1+, BL, n=11 | 0 |
| UP, 2+, BL, n=11 | 0 |
| UP, 3+, BL, n=11 | 0 |
| UP, 4+, BL, n=11 | 0 |
| UG, MS, BL, n=11 | 0 |
| UG, NR, BL, n=11 | 1 |
| UG, Neg, BL, n=11 | 10 |
| UG, normal, BL, n=11 | 0 |
| UG, 5, BL, n=11 | 0 |
| UG, 15(1+), BL, n=11 | 0 |
| UG, 30(2+), BL, n=11 | 0 |
| UG, 60(3+), BL, n=11 | 0 |
| UG, 110(4+), BL, n=11 | 0 |
| UK, MS, BL, n=11 | 0 |
| UK, NR, BL, n=11 | 1 |
| UK, Neg, BL, n=11 | 10 |
| UK, Trace(5), BL, n=11 | 0 |
| UK, Small(15), BL, n=11 | 0 |
| UK, Moderate(40), BL, n=11 | 0 |
| UK, Large(80), BL, n=11 | 0 |
| UK, Large(160), BL, n=11 | 0 |
| UOB, MS, BL,n=11 | 2 |
| UOB, NR, BL,n=11 | 1 |
| UOB, Neg, BL,n=11 | 5 |
| UOB, 1+, BL,n=11 | 1 |
| UOB, 2+, BL,n=11 | 0 |
| UOB, 3+, BL,n=11 | 0 |
| UOB, Non haemolysed trace, BL,n=11 | 0 |
| UOB, haemolysed trace, BL,n=11 | 0 |
| pH, MS, BL, n=11 | 0 |
| pH, NR, BL, n=11 | 1 |
| pH, normal result, BL, n=11 | 0 |
| pH, Neg, BL, n=11 | 0 |
| pH, 5, BL, n=11 | 2 |
| pH, 5.5, BL, n=11 | 1 |
| pH, 6, BL, n=11 | 4 |
| pH, 6.5, BL, n=11 | 1 |
| pH, 7, BL, n=11 | 1 |
| pH, 7.5,BL, n=11 | 1 |
| pH, 8, BL, n=11 | 0 |
| pH, 8.5, BL, n=11 | 0 |
| pH, 9, BL, n=11 | 0 |
| UP, MS, W24, n=34 | 2 |
| UP, NR, W24, n=34 | 0 |
| UP, Neg, W24, n=34 | 32 |
| UP, Trace, W24, n=34 | 0 |
| UP, 1+, W24, n=34 | 0 |
| UP, 2+, W24, n=34 | 0 |
| UP, 3+, W24, n=34 | 0 |
| UP, 4+, W24, n=34 | 0 |
| UG, MS, W24, n=4 | 1 |
| UG, NR, W24, n=4 | 0 |
| UG, Neg, W24, n=33 | 29 |
| UG, normal, W24, n=33 | 3 |
| UG, 5, W24, n=33 | 0 |
| UG, 15(1+), W24, n=33 | 0 |
| UG, 30(2+), W24, n=33 | 0 |
| UG, 60(3+), W24, n=33 | 0 |
| UG, 110(4+), W24, n=33 | 0 |
| UK, MS, W24, n=33 | 1 |
| UK, NR, W24, n=33 | 0 |
| UK, Neg, W24, n=33 | 32 |
| UK, Trace(5), W24, n=33 | 0 |
| UK, Small(15), W24, n=33 | 0 |
| UK, Moderate(40), W24, n=33 | 0 |
| UK, Large(80), W24, n=33 | 0 |
| UK, Large(160), W24, n=33 | 0 |
| UOB, MS, W24, n=33 | 1 |
| UOB, NR, W24, n=33 | 0 |
| UOB, Neg, W24, n=33 | 31 |
| UOB, 1+, W24, n=33 | 0 |
| UOB, 2+, W24, n=33 | 0 |
| UOB, 3+, W24, n=33 | 0 |
| UOB, Non haemolysed trace, W24, n=33 | 0 |
| UOB, haemolysed trace, W24, n=33 | 0 |
| pH, MS, W24, n=34 | 0 |
| pH, NR, W24, n=34 | 0 |
| pH, normal result, W24, n=34 | 0 |
| pH, Neg, W24, n=34 | 0 |
| pH, 5, W24, n=34 | 0 |
| pH, 5.5, W24, n=34 | 4 |
| pH, 6, W24, n=34 | 10 |
| pH, 6.5, W24, n=34 | 4 |
| pH, 7, W24, n=34 | 11 |
| pH, 7.5,W24, n=34 | 3 |
| pH, 8, W24, n=34 | 2 |
| pH, 8.5, W24, n=34 | 0 |
| pH, 9, W24, n=34 | 0 |
An adverse event (AE) is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose: results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability or incapacity, or is a congenital anomaly or birth defect. Medical or scientific judgment should be exercised in other situations.
| Participants | Part 1 (Dose-Finding Period) Cohort 1 | Part 1 (Dose-Finding Period) Cohort 2 | Part 1 (Dose-Finding Period) Cohort 3 |
|---|---|---|---|
| Any AE | 5 | 5 | 5 |
| Any SAE | 1 | 1 | 0 |
An adverse event (AE) is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose: results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability or incapacity, or is a congenital anomaly or birth defect. Medical or scientific judgment should be exercised in other situations.
| Participants | Part 2 (Randomized Period) Cohort 1-Placebo | Part 2 (Randomized Period) Cohort 1- Eltrombopag | Part 2 (Randomized Period) Cohort 2-Placebo | Part 2 (Randomized Period) Cohort 2-Eltrombopag | Part 2 (Randomized Period) Cohort 3-Placebo | Part 2 (Randomized Period) Cohort 3- Eltrombopag |
|---|---|---|---|---|---|---|
| Any AE | 8 | 13 | 9 | 14 | 3 | 9 |
| Any SAE | 1 | 1 | 1 | 3 | 0 | 0 |
An adverse event (AE) is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose: results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability or incapacity, or is a congenital anomaly or birth defect. Medical or scientific judgment should be exercised in other situations.
| Participants | Part 2/3 (Eltrombopag Open-Label Period) Cohort 1 | Part 2/3 (Eltrombopag Open-Label Period) Cohort 2 | Part 2/3 (Eltrombopag Open- Label Period) Cohort 3 |
|---|---|---|---|
| Any AE | 22 | 26 | 14 |
| Any SAE | 3 | 5 | 0 |
The visual acuity assessment was performed by an ophthalmologist or an optometrist under the guidance of an ophthalmologist. Visual acuity is defined as acuteness or clearness of vision. The number of participants with a change in visual acuity and worsening visual acuity due to cataracts since Baseline are presented for Part 1 Follow-up Visits at 3-months (FU3) and at 6-months (FU6). Change in visual acuity since Baseline is displayed under the left eye but applies to both eyes. Change in visual acuity (VA) is categorized as "yes" or "no". Change due to cataracts is categorized as "yes" or "no".
| Participants | Part 1 (Dose-Finding Period) Cohort 1 | Part 1 (Dose-Finding Period) Cohort 2 | Part 1 (Dose-Finding Period) Cohort 3 |
|---|---|---|---|
| Change in VA at FU3, no | 1 | 1 | 2 |
| Change in VA at FU3, yes | 0 | 0 | 1 |
| Change in VA at FU6, no | 4 | 4 | 5 |
| Change in VA at FU6, yes | 0 | 0 | 0 |
| Change due to cataracts at FU3, no | 0 | 0 | 1 |
| Change due to cataracts at FU3, yes | 0 | 0 | 0 |
| Change due to cataracts at FU6, no | 0 | 0 | 0 |
| Change due to cataracts at FU6, yes | 0 | 0 | 0 |
The visual acuity assessment was performed by an ophthalmologist or an optometrist under the guidance of an ophthalmologist. Visual acuity is defined as acuteness or clearness of vision. Number of participants with a change in visual acuity and change in visual acuity due to the worsening of cataracts since Baseline are presented for Part 2/3 Follow-up Visits at 3-months (FU3) and 6-months (FU6). Change in visual acuity since Baseline is displayed under the left eye but applies to both eyes. Change in visual acuity (VA) is categorized as "yes" or "no". Change due to cataracts is categorized as "yes" or "no".
| Participants | Part 2/3 (Eltrombopag Open-Label Period) Cohort 1 | Part 2/3 (Eltrombopag Open-Label Period) Cohort 2 | Part 2/3 (Eltrombopag Open- Label Period) Cohort 3 |
|---|---|---|---|
| Change in VA at FU3, no | 13 | 17 | 9 |
| Change in VA at FU3, yes | 4 | 1 | 2 |
| Change in VA at FU6, no | 16 | 22 | 6 |
| Change in VA at FU6, yes | 4 | 2 | 3 |
| Change due to cataracts at FU3, no | 4 | 1 | 2 |
| Change due to cataracts at FU3, yes | 0 | 0 | 0 |
| Change due to cataracts at FU6, no | 4 | 2 | 3 |
| Change due to cataracts at FU6, yes | 0 | 0 | 0 |
Collected over On-treatment adverse events (AEs) and serious adverse events (SAEs) are defined as events occuring from the start of the investigational product until the end of treatment (up to Study Week 31). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1 (Dose-Finding Period) | — | 2/15 (13.3%) | 15/15 (100%) |
| Part 2 (Randomized Period) -Placebo | — | 2/21 (9.5%) | 20/21 (95.2%) |
| Part 2 (Randomized Period) - Eltrombopag | — | 4/44 (9.1%) | 36/44 (81.8%) |
| Part 2/ 3 (Eltrombopag Open-Label Period) | — | 8/65 (12.3%) | 62/65 (95.4%) |
| Event | Part 1 (Dose-Finding Period) | Part 2 (Randomized Period) -Placebo | Part 2 (Randomized Period) - Eltrombopag | Part 2/ 3 (Eltrombopag Open-Label Period) |
|---|---|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 1/15 | 0/21 | 1/44 | 1/65 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 1/15 | 1/21 | 0/44 | 1/65 |
| ImpetigoInfections and infestations | 0/15 | 1/21 | 0/44 | 0/65 |
| VaricellaInfections and infestations | 0/15 | 1/21 | 0/44 | 0/65 |
| ConjunctivitisEye disorders | 0/15 | 1/21 | 0/44 | 0/65 |
| AnaemiaBlood and lymphatic system disorders | 0/15 | 0/21 | 1/44 | 1/65 |
| Febrile neutropeniaBlood and lymphatic system disorders | 0/15 | 0/21 | 1/44 | 1/65 |
| PyrexiaGeneral disorders | 0/15 | 0/21 | 1/44 | 1/65 |
| Urinary tract infectionInfections and infestations | 0/15 | 0/21 | 1/44 | 1/65 |
| Lenticular opacitiesEye disorders | 0/15 | 0/21 | 0/44 | 1/65 |
| Event | Part 1 (Dose-Finding Period) | Part 2 (Randomized Period) -Placebo | Part 2 (Randomized Period) - Eltrombopag | Part 2/ 3 (Eltrombopag Open-Label Period) |
|---|---|---|---|---|
| HeadacheNervous system disorders | 8/15 | 9/21 | 13/44 | 28/65 |
| VomitingGastrointestinal disorders | 6/15 | 6/21 | 4/44 | 10/65 |
| Upper respiratory tract infectionInfections and infestations | 5/15 | 2/21 | 11/44 | 24/65 |
| DiarrhoeaGastrointestinal disorders | 5/15 | 1/21 | 7/44 | 17/65 |
| NauseaGastrointestinal disorders | 1/15 | 6/21 | 6/44 | 15/65 |
| Abdominal painGastrointestinal disorders | 2/15 | 2/21 | 3/44 | 15/65 |
| PyrexiaGeneral disorders | 0/15 | 3/21 | 6/44 | 15/65 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 3/15 | 3/21 | 1/44 | 11/65 |
| CoughRespiratory, thoracic and mediastinal disorders | 1/15 | 0/21 | 3/44 | 9/65 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 1/15 | 1/21 | 5/44 | 9/65 |
| Age, Continuous(Years) | Part 1 Eltrombopag Dose-Finding Period | Part 2 (Randomized Period) Cohort 1-Placebo | Part 2 (Randomized Period) Cohort 1- Eltrombopag | Part 2 (Randomized Period) Cohort 2-Placebo | Part 2 (Randomized Period) Cohort 2-Eltrombopag | Part 2 (Randomized Period) Cohort 3-Placebo | Part 2 (Randomized Period) Cohort 3- Eltrombopag | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 9.1 ± 4.61 | 14.6 ± 1.69 | 13.7 ± 1.58 | 8.6 ± 2.24 | 8.2 ± 1.87 | 3.6 ± 1.34 | 3.3 ± 1.34 | 9.3 ± 4.49 |
| Sex: Female, Male(Participants) | Part 1 Eltrombopag Dose-Finding Period | Part 2 (Randomized Period) Cohort 1-Placebo | Part 2 (Randomized Period) Cohort 1- Eltrombopag | Part 2 (Randomized Period) Cohort 2-Placebo | Part 2 (Randomized Period) Cohort 2-Eltrombopag | Part 2 (Randomized Period) Cohort 3-Placebo | Part 2 (Randomized Period) Cohort 3- Eltrombopag | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 8 | 3 | 8 | 8 | 14 | 2 | 5 | 48 |
| Male | 7 | 5 | 8 | 1 | 5 | 3 | 5 | 34 |
| Race/Ethnicity, Customized(Participants) | Part 1 Eltrombopag Dose-Finding Period | Part 2 (Randomized Period) Cohort 1-Placebo | Part 2 (Randomized Period) Cohort 1- Eltrombopag | Part 2 (Randomized Period) Cohort 2-Placebo | Part 2 (Randomized Period) Cohort 2-Eltrombopag | Part 2 (Randomized Period) Cohort 3-Placebo | Part 2 (Randomized Period) Cohort 3- Eltrombopag | Total |
|---|---|---|---|---|---|---|---|---|
| African American/African Heritage | 2 | 0 | 0 | 0 | 1 | 0 | 0 | 3 |
| Asian - Japanese/East Asian Heritage | 2 | 1 | 0 | 1 | 1 | 0 | 1 | 6 |
| White - White/Caucasian/European | 9 | 7 | 14 | 8 | 17 | 5 | 7 | 67 |
| Unknown | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| White - Arabic/North African Heritage | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 2 |
| Mixed Race | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 3 |
The record gives a start of Sep 2009, a primary completion of Feb 2014 and a completion of Feb 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2014, 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Eltrombopag
Purpura, Thrombocytopenic, Idiopathic →